TABLE DI YEAR GAVAGE STUDY OF HYDROQUINONE

.
TABLE DI
SUMMARY OF THE INCIDENCE OF NIEC7PI .ASMS IN FEMALE MICE IN THE TWOYEAR GAVAGE STUDY OF HYDROQUINONE
198
TABLE I12
INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE TWO-YEAR
GAVAGE STUDY OF IiY1Dk2OQUINf7AlE
204
TABLE D3
ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR GAVAGE
STUDY OF HYDROQUINONE
231
TABLE 134a
HISTORICAL INCIDENCE OF HEP1iTOCELI.LTLAR TUMORS IN FEMALE B6C3F°r MICE
233
TABLE 174b
HISTORICAL INCIDENCE OF THYROID GLAND FOLLICULAR CELL TUMORS IN
FEMALE B6C3F1 MICE
234
TABLE I35
SUMMARY OF THE INCIDENCE OF NO1VNEOPLASTFC LESIONS FN FEMALE MICE IN
THE TWO-YEAR GAVI4GE STUDY OF HYDROQUINONE
235
197
Hydp«quinane, N°sP TR 366
TABLE D1 . SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR
GAVAGE STUDY OF HYDROQUINONE
Vehicle .Control
Animals initially in study
Animals removed
Animals examined histopathologically
ALIMENTARY SYSTEM
Gallbladder
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Intestine large, cecum
Lymphoma malignant lymphocytic
Lymphoma malignant
Intestine large,colon
Lymphoma malignant lymphocytic
Intestine small,duodenum
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Serosa, fibrosarcotna, metastatic, mesentery
Intestine small, ileum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
65
65
55
Low Dose
65
65
55
(50)
2 (4%)
(62)
1 (29'0)
(52)
(52)
1 (2%a)
1 (2%)
65
65
55
*(55)
i (2%)
Intestine small, jejunum
Lymphoma malignant lymphocytic
(52)
1 (2~'0)
*(55)
3 (2%)
Liver
Cholangiocarcinoma, metas4ztic
Hemangiotna
Hemangiosarcoma
Hepatmcellular carcinoma
Hepatocellular adenoma
Y-Iepatacellular adenoma, multiple
i-Iistiacy2ic sarcoma
(5S)
2 (4%)
2
4
F
2
(2%)
(2%)
(2°!0)
(43b)
Lymphoma malignant lymphocytic
3
Lymphoma malignant
2
Lymphoma malignant mixed
4
Lymphoma malignant undifferentiated cell type
Mesentery
*(55)
Cholangaocarcinocraa, metast.atic
Fibrasarcoxrsa
Fibrosarcoma, multiple
Lymphoma malignant lymphocytic
3
(59'0)
(4qo)
(7%)
Lymphoma malignant I11SCI.OCyt1C
Lymphoma malignant
(5%)
1 (2%)
Lymphoma malignant mixed
Fat, lymphoma malignant
Pancreas
Fibrosarcoma, early invasion, metastatic,
1 (2°'%)
1 (2%)
(54)
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Salivary glands
Histiocytic sarcoma
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Stomach
1 (23'0)
1 (2%)
2 (4%)
(64)
Stomach, forestomach
Papillmssa squamous
Glandular, lymphoma malignant lymphocytic
(54)
mesentery
Serosa, lymphoma malignant lymphocytic
1YyLSrOquISIOney
NTP Tfft 366
3 (6g'o)
1 (2Rb)
2 (4%)
(54)
1 (2°l0)
198
(>i)
3 (6~'0)
1 (2%)
(52)
2 (4%)
1 (23'0)
1 (2%)
(55)
1 (2%)
1 (2%)
(48)
(53)
1 (2%a)
` $ (2%)
(52)
*(55)
% (2%)
*(55)
(49)
1 (2%)
Lymphoma malignant mixed
'
*(5S)
Y . (2%)
*(55)
2 (49'a)
Jejunum, lymphoma malignant mixed
High Dose
.
(b2)
3 (63'0)
1 (2%)
(55)
2 (4%)
12 (20%)
4 47%a3
1
(L%)
'°`d557
1
H
$
2
(2%)
(29'0)
(2q'a)
(4%)
4 (7%)
1 (2Wo)
2 (4%)
-
2
11
1
1
1
3
3
3
1
"(55)
(49'0)
(20~'0)
(2%)
(2%)
(2%)
(b%)
(5%)
(5%)
(2°!0)
fl (2%)
"'(55)
1 (2%)
2 (4%)
(54)
2 {4%)
1 (2%)
(53)
2 (4%)
(64)
1 (2%a)
2 (4g'o)
*(55)
(55)
*(55)
1 (2%)
(55)
1 (2%a)
.
'
TABLE Da. SUMMARY OF THE INCIDENCE OF NEOPr.AsMS IN FEMALE rMCE IN THE TWO-YEAR :
GnVAGE STUDY OF HYDROQUINONE (Continued)
Vehicle Control
:
ALIMENTARY SYSTEM (Continued)
Stomach, glandular
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
(b3)
1 (2%)
! (2%)
1 (2%)
CARDIOVASCULAR SYSTEM
(55)
Heart
1 (2%)
Lymphoma malignant lymphocytic
1 (2%}
Lymphoma malignant
Lymphoma malignant mixed
1 (2~'0)
Epicardivm, lymphoma malignant lymphocytic
Pericardium, lymphoma malignant
undifferentiated cell type
ENDOCRINE SYSTEM
Adrenal gland
Capsule, Ct1U1SriglOCBIC1l20P'Tifl,IriBteA5Y,8$lc
(55)
Capsule, lymphoma malignant lymphocytic
Capsule, lymphoma malignant
Capsule, lymphoma malignant mixed
Adrenal gland, cortex
Lymphoma malignant lymphocytic
Lymphoma malignant
1
1
1
(55)
1
1
Adrenal gland, medulla
(51)
Pheochromacytoma benign
Islets, pancreatic
Lymphoma malignant mixed
Pituitary gland
Pacsdistalis,adenoma
Pars disCs3is, carcinoma
Pars intermedia, adenoma
Thyroid gland
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma. malignant mixed
Follicular cell,adenoma
Follicular cell, carcinoma
(51)
2
(6B)
11
1
1
(55)
I
1
fl
3
Lymphoma malignant mixed
Lymphoma malignant undifferentiated cell type
Pheochromocytoma malignant
GENERAL BODY SYSTEM
Tissue, NOS
Sarcoma, poorly differentiated
GENITAL SYSTEM
Ovary
Adenoma.
Cystadetioma
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Osteosarcoma, metastatie, bone
Tera4:oma
F'eriovarian tissue, lymphoma malignant
lymphocytic
Low Dose .
*(55)
(55)
1 (2%)
*(55)
1 (2%)
1 (2%) ,
1 (2°l0)
(2°10)
(Zg'o)
1 (2%)
i c2%>
(2%)
(21R'o)
(2%)
(2°10)
(2%)
(2%)
(2%)
(59'a)
*(56)
1 (2~'0)
1
(5b)
(`L%)
1 (2%)
*(55)
(55)
3 (5%)
1 (2%)
1 (2°10)
*(55)
(b2)
*(55)
(5Z)
*(55)
lA (25%)
2 (4`Yo)
(52)
11 (21%)
(55)
2 (4°!0)
1 (2%)
1 (2%)
1 (23'0)
3 (5%)
199
1 (2%)
(55)
1 (2°l0)
5 (9%)
*(56)
6 (fli3'o)
1 (2%)
"(55)
(63)
I (25`0)
(55)
(b5)
1 (2%)
*(55)
(2~"0)
(2%)
(23'o)
High Dose
(54)
I (2%)
4 (&%)
1 (2%a)
1
1 (2%)
fl
(2%)
(2°la)
3 (6%)
F-Iydraquinone, NTP TR 366
TABLE I3.1 . SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MI CE IN THE TWO-YEAR
GAVAGE STUDY OF HYDROQUINONE (Continued)
Vehicle Control
GENITAL SYSTEM
Ovary (Continued)
(55)
Peeiovarian tissue, lymphoma malignant
I (23'0)
F`eziovarian tissue, lymphoma malignant mixed
2 (4%)
Periovarian tissue, lymphoma malignant
undifferentiated cell type
Uterus
(b4)
Fiemangioma
Lymphoma malignant lymphocytic
2 (43'0)
Lymphoma malignant mixed
1 (2%)
Polyp stromal
Serosa, lymphoma malignant
1 (2%) ,
HEMATOPOIETIC SYSTEM
Bone marrow
Lymphoma malignant lymphocytic
Lymph node
Lymphoma malignant lymphocytic
Lymphoma malignant
Axillary, lymphoma malignant histiocytic
A sillary, lymphoma malignant lymphocytic
Agillary, lymphoma malignant
Bronchial, lymphoma malignant lymphocytic
Bronchial, lymphoma malignant mixed
Deep cervical, lymphoma malignant mixed
Iliac, lymphoma malignant lymphocytic
Iliac, lymphoma malignant
Iliac, lymphoma malignant mixed
Inguinal, lymphoma malignant lymphocytic
Inguinal, lymphoma malignant
Inguinal, lymphoma malignant mixed
Lwnbar, lymphoma malignant histiocytic
Lumbar, lymphoma malignant lymphocytic
Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
Lumbar, osteosarcorna, metastatic, bone
Mediastinal, lymphoma malignant lymphocytic
Mediastinal, lymphoma malignant
Mediastinal, lymphoma malignant mixed
Pancreatic, histiocytic sarcoma
Pancreatic, lymphoma malignant histiocytic
Pancreatic, lymphoma malignant lymphocytic
Pancreatic, lymphoma malignant
Pancreatic, lymphoma malignant mixed
PopliteaI, lymphoma malignant lymphocytic
Popliteal, lymphoma malignant
(55)
1 (2%)
(55)
1 (29'o)
1 (2%)
1 (29'0)
1 (2%)
1 (2%)
1 (2°Io)
Y (2%)
1 (2Wa)
Hyrdroquinone,lVTP TR 366
(53)
1 (23'0)
2 (4%)
3 (5%)
3 (5%)
1 (2%)
2 (4%)
I (2°lo)
1 (2%)
4 (7%)
Pi (21°l0)
200
High Dose
(54)
1 (29'0)
1 (2%)
*(55)
P (2%)
I (29'o)
1 (29'0)
(55)
1 (2%)
*(55)
(54)
*(65)
(54)
1 (2°Jo)
1 (2%)
(2%)
1 d2g'o9
I (2%)
k (2%)
1 (2qo)
1 (2%)
(2%)
Renal, lymphoma malignant lymphocytic
2 (4%)
Renal, lymphoma malignant
1 (2%)
Renal, lymphoma malignant mixed
Thoracic, lymphoma malignant lymphocytic
I (29'0)
Lymph node, mandibular
(50)
Eiistiocytic sarcoma
Lymphoma malignant histiocytflc
Lymphoma malignant lymphocytic
6 (22°!0)
Lymphoma malignant
2 (4%)
Lymphoma malignant mixed
2 (4°,ln)
Lymphoma malignant undifferentiated cell type
Lymph node, mesenteric
(S2)
Hfstiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Low Dose
3
2
2
1
2
1
2
(5%)
(2%)
(4%)
(2%)
(4%)
(2~Y'o)
(4%)
1 (Z%)
1 (2%)
1
1
I
3
(2°!0)
(23'0)
(29''0)
(6%)
2
Y
1
1
(4%)
(2g'o)
(29'0)
(23'0)
1
Y
2
2
(2%)
(2%)
(4%)
(496)
2 (4%)
1 (2%)
1
1
3
I
1
(2%)
(2g'o)
(63'0)
(2%)
(2%)
1 (2%)
1 (2°!0)
'°(6~?
3 (5%)
1 (2%)
2 (4%)
*(5b)
3 (59°0)
(49)
1
1
6
2
2
1
(62)
1
1
7
(2%)
(2g'o)
(12%)
(4%)
(4°l0)
(29'0)
(2g'o)
(2%a)
(235b)
HENiATOPOYETIC SYSTEM
(52)
Lymph node, mesenteric (Continued)
3 (6'0)
Lymphoma malignant
5 (1096)
Lymphoma malignant mixed
Lymphoma malignant undifferentiated cell type
Renal, cholangiocarcinoma, metastatic .
t55?
Spleen
Lymphoma malignant histiocyCic
10 (183'0)
Lymphoma malignant lymphocytic
3 (5°Ya)
Lymphoma malignant
7 (I3~'o)
Lymphoma malignant mixed
Lymphoma malignant undifferentiated cell type
Capsule, cholangiocarcinoma, anetastatic
(44)
Thymus
Lymphoma malignant histiocytic
4 (9%)
Lymphoma malignant lyrnphocytic
Lymphoma malignant
3 (°7%)
Lymphoma malignant mixed
Lymphoma malignant undifferentiated cell type
TNTEGUMElVTARY SYSTEM
(52)
Mammary gland
3 (6%)
Adenocarcinoma
Cholangiocarcinoma, metastatic, multiple
1 (2%)
Lymphoma malignant lymphocytic
Lymphoma malignant
Thoracic, hepatoceltnlar carcinoma, mef:astiatic,
liver
(5b)
Skin
fl
Basal cell carcinoma
Y
Subcutaneous tissue, fibrosarcoma
Subcutaneous tissue, hepatacelluflar carcinoma,
metastatac, liver
Subcutaneous tissue, lymphoma malignant
1.
Iymphocytic
1
Subcutaneous tissue, lymphoma malignant
1
Tail, neurofibrosarcoma
Thoracic, subcutaneous tissue, hersaangiosareoma
RdiJSCCJLOSICELETAL SYSTEM
e
Lumbar, vertebra, osteosarcoma
Vertebra, cholangiocarcinorna,meCastatie
Skeletal muscle
Lymphoma malignant
(2%)
(Z%)
(52)
3 (6%)
5 (10%)
1 (2%)
*(55)
1 (2%)
3 (5%)
,
t (2%)
*(55)
(55)
7 (13~"a)
1 (2%m)
4 (7%)
fl (2%)
*(5b)
3 (b%)
1 (29'0)
fl t2%i
'"(56)
b
1
2
Z
'
(9%?
(2°!0)
(4%)
(2%)
1 (29'a)
*(55)
`
7
3
4
i
(139'0)
(53'0)
(7%)
(2%)
(47)
4
1
1
1
(99o)
(2%)
(2%)
(290)
(53)
2 (4%)
(55)
2 (2'Yo)
I (2%)
(2%)
d29'o3
C2%B
1 (2%)
1 (2%)
Y (2%)
(bS)
*t55>
(55)
'"(55)
}(55)
*(55)
Abdominal, fibrosarcoma, early invasion,
metastatic, mesentery
Abdominal, diaphragm, chalangiocarcinoma,
metastatic
1 (2%)
1 (2%)
1 t2%3
NERVOUS SYSTEM
(55)
Brain
Carcinoma, extension, metastatic, pituitary
E (2%)
gland
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Il (2%)
Cerebrum, oligadendraglioma malignant
Perivascnlar, lymphoma malignant lymp4nocytic
Perivascular, lymphoma malignant
201
*(55)
1 (2%)
Z (Zq°)
(55)
1 (2°l0)
1 (2%)
1 (2'°3
Hydx°oqu%none, NTP TR 366
TABLE Dl . SUMMARY OF THE INCIDENCE OF rrEoPLAsMs ix FEMALE MICE IN THE TWO-YEAR
GAVAGE STUDY OF HYDROQUINONE (Continued)
Vehicle Control
RESPIRATORY SYSTEM
Lung
Alveolar/bronchiolar adenoma
Alveolar/bronchiolar adenoma, multiple
Alveolar/bronchiolar carcinoma
Basal cell carcinoma, metastatic
Carcinoma, metastatic
Hegsatoce3lular carcinoma, metastatic, liver
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
(5S)
3 (5'Yo)
Pleura, lymphoma malignant Iyrnphacytic
Trachea
Lymphoma malignant mixed
SPECIAL SENSES SYSTEM
Ear
Canal, external ear, squamous cell carcinoma
Fiarderian gland
Adenoma
Carcinoma
I.yxnphoma malignant mixed
URINARY SYSTEM
Kidney
I'IEFI$LiDCEIILIIAY carcinoma, TIB8t8&t&$l.C
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Osteosarcoma, metastatic, bone
Capsule, cholangiocarcinoma, metastatic
Capsule, lymphoma malignant lymphocytic
Fat, lymphoma malignant mixed
Renal tubule, adenoma
Urinary bladder
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
SYSTEMIC LESIONS
Multiple organs
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Lymphoma malignant
Iiemangiosarcoma
Hernangioma
Lymphoma malignant histiocyCic
Lymphoma malignant undifferentiated cell
Fiydroqtxinone, IVTP TR 366
(55)
6 (1196)
1 (23'0)
1 (29o)
Lymphoma malignant undifferentiated cell type
oS4GosarCOmay meN1J~YG441~iy b
one
Low Dose
4 (7°Jo)
3 (5%)
2 (4%)
1 (2~9'0)
(54)
2 (2°l0)
*(5b)
1 (2%)
*(55)
2 (qqo)
2 (2g'o)
2 (4~'a)
3. (2%)
(29'o}
F (23'0)
I (2%)
1 (2qo)
(53)
4 (g960
L (2g6)
1 (2rYo)
*(55)
14
7
3
1
2
(25%)
(13%)'
(5~'0)
(23'0)
(2%)
202
1 (2%)
2
3
2
a
(23'0)
(5%)
t4%3
c2%>
(55)
"'f559
*(55)
*(55)
2 (4%)
*(55)
2 (4%)
2 (49'0)
*(55)
4 (7%)
2 (4%)
2 (4%)
(b5)
1 (2%)
1 (2%)
2 (4%)
*(55)
1 (23'0)
(55)
High Dose
1
(2%)
3
1
1
1
g
(5%)
(2e%)
(2%)
(2%)
(2qo)
*(6b)
1 (2 %)
g (5opa)
1 (2g'o)
*(55)
'X (13%)
5 (9°l0)
1 (29'0)
2 (4~Y'o)
1 (25b)
t5b)
1
4
3
3
(2%O)
(79'0)
(5%)
(53'0)
1 (29'0)
1 (2°l0)
(54)
1 (2%)
°(b5)
9
6
3
1
(l6%)
(11R'o)
(5%)
(2%)
1 (230)
k (2qy)
,
TABLE Dfl . SUMMARY OF THE INCIDENCE OF NEOIaLASMS IN FEMALE MICE IN THE TWO-YEAR
tAAVAGE STUDY OF FII'DROQLTYNOPtE (Continued)
Vehicle Control
ANIMAL DISPOSITION SUMMARY
Animals initially in study
Terminal sacrifice
Moribund
Interval sacrifice
Dead
Accident
i
TUMOR . SUMMARY
Total animals with primary neoplasms *"
Total primary neoplasms
Total animals with benign neoplasms
Total benign neoplasfns
Total animals with malignant neoplasms
Total malignant neoplasms
Total animals with secondary neaplasms
Total secondary neoplasms .
Low Dose
High Dose
65
37
7
10
11
65
39
11
10
5
65
43
64
21
26
31
38
2
2
42
7&
33
47
21
29
4
21
39
71
27
36
27
35
F
1
10
9
4
'~ Number of animals receiving complete necropsy examination ; all gross lesions including masses examined microscopically .
*~ Primary tumors : all tumors except secondary tumors
**'° Secondary tumors : meCastatic tumors or tumors invasive into an adjacent organ
203
Hydroquinone, NTP TIZ 366
TABLE D2. INDIVIDUAL . ANIMAL TUMOR PATHOLOGY ()F FEMALE
CE IN THE :TWO-YEAR
GAVAGE STUDY (3F YiI'Y3Ii,t9QUYNONE : VEHICLE CONTROL
WEEKS ON -- -
o- 0 0 0 0
STUDY
CARCASS
ID
E
h
l1laNd'."
Lymphoma malignant mixed
Intestine large
Intestine large, cecum
Lymphoma malignant lymphocytic
Intestine large, colan
Intestine large, rectum
Intestine small
Intestine small, duodenum
Lymphoma malignant lymphocytic
Lymphoma malignant
Intestine small, ileum
Lymphoma malignant lymphocytic :
Intestine small, jejunum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Liver
.
..
Hemangioma
Homangiosareom8
Repatocellular carcinoma
Hepatocellular adenoma
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Mesentery
Lymphoma malignant lymphocytic
Lympmoma malignant
Lymphoma malignant mixed
Fat, lymphoma malignant
.
..
0 0 0 0 0 0 0 0 0 1
1
5
8
6
2
6
7
7
1
7
9
8
0
8
4
8
6
9
1
9
1
9
4
9
5
9
7
9
9
9
9
0
0
0
5
0
5
0
5
0
5
0
5
0
5
S
5
6
5
1
5
8
5
3
5
4
1
2
4
9
5
2
4
2
3
0
4
6
.2
2
3
0
5
0
4.
3
4
1
2
0
3
0
1
0
2
3
2.
3
3
4
4
4
5
5,3
.
+
.
M
.
+
.
A
.
+
.
A
.
+
.
A
.
+
.
+
.
+
.
+
.
A
.
+
.
+
.
+
.
+
.
+
.
+
.
+
.
+
.
+
.
+
.
+
A
+
+
+
+
+
+
Ei
A
+
A
+
+
+
+
+
+
.
+
g
+
+
+
+
ii-
+
+
+
+
+
+
+
+
t
+
+
t
i+
+
+
+
+
-F
.
+
+
+
+
+
+
A
+
A
+
+
+
+
+
A
+
f
-t+
rL
t1
A
A
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-t+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-F
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-o-
+
+
+
+
+ . +
+
+
+
+
+ +
+
+
+
+
r1
A
+
A
R
A
+
A
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
A
A
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ . +. .
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
-F
X
+
+
+
%
.
.
.
X
g
X
X
+
+
.
+
+
M
+
+
+
+
+
+
+
-o+
X
.
ENDOCRINE SYSTM
Adrenal gland
Capsule, lymphoma malignant
lymphocytic
Capsule, lymphoma malignant
Capsule, lymphoma malignant mixed
Adrenal gland, cortex
Lymphoma malignant lymphocytic
Lymphoma malignant
Adrenal gland, medulla
PheocHromocytoma malignant
Pheochromocytoma benign
Islets, pancreatic
Lymphoma malignant mixed
Parathyroid gland
Pituitary gland
Pais distalis, adenoma
Pars distalis, carcinoma
Pars iatermedia, adenoma
Thyroid gland
LympLoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Follicularcell,adenoma
+
.+
+
+
+
+
+
-F
+
tr
+
+
+
+
+
+
+
+
+
+
+
+
+
+
g
+
+
+
+
M
+
-h
+
+
+
+
+
X
+
+
+
+
+
f
+
i-
+
+
+
+
+
+
+
+
+
.+
+
+
+
+
+
+
+
+
+
+
+
+
+ - +
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
M
X
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-h
+
.
+
X
+
+
+
+
X
+
+
++
+
g
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
M
+
+
+
+
1VY
+
M
A
+
+
+
+
+
.
..
+
+
+
+
+
+
+
+
+
+
+
+
+
M
+
M
+
+
+
+
+
+
-E
+
+
M
+
+
.
t
+
+
+
+
+
+
+
+
+
+
+
R
+
+
X
+
+
+
.
+
.
+
+
X
M
+
+
+
M
I
+
+
%
M
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
-t-
+
+
+
+
+
+
+
+
+
+
+
g
+
X
-
Tissue, Y30S
Sarcoma, poorly differentiated
X
Tissue examined microscopically
Not examined
Present but not examined microscopically
Insufficient tissue
Hydroquinone,lVTP TR 366
X
+
+
X
+
0
5
.
f
g
CARDIOVASCULAR SYSTEM
Heart Lymphoma malignant lymphocytic
Lymphoma malignant
Epicardium, lymphoma malignant
Flymphocytic
+:
:
-:
Z:
1
5
4
-
Pancreas
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Salivary glands
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Stomach
Stomach,forestomach
Glandular, lymphoma malignant
lymphocytic
Stomach, glandular
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
0 0 0
4
2
M:
A
%:
2~4
Missing
Autolysis precludes examination
Incidence of listed morphology
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: VEHICLE CONTROL
(Continued)
WEEKS
STUDY
N
CARCASS
ID
2 11
0
0
0
5
5
5
1
0
5
I
0
5
e
0
5
1
0
5
1
0
5
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
1
0 ' 0
6
6
1
0
6
1
0
6
1
0
6
6 . 7
1 3
d
8
3
9
3
4
9
4
5
0
3
1
4
~
2
1
2
2
4
3
~s
5
2
7
1
7
2
8
2
9
1
9
2
v
0
2
1
3
3-4
1
2
2 . 1
1
3
7
4
0
1
1
0
6
1---l1~~
0
0
0
6
6
6
3
1
4
2
+
i-
+
+
+
+
+
+
+
+
+
+
¢
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
t
~+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
t
+
+
.
+
+
+
+
+
Intestine Large, colon
Intestine large, rectum
+
+
+
+
X
+
Intestine large, cecum
+
+
.
+
+
+.
+
+
.
4
+
+
+
t
+
+
+
r
+
a+
i.
+
+
+
+
.
+
.
+
+
+
+
+
+
a-
+
+
+
+
+
a
+
+
+
Esopha~us
Gallb2adder
Lymphoma malignant mixed
Intestine large
Lymphoma malignant lymphocytic
+
+
Intestine small
Intestine small, duodenum
Lymphoma malignant lymphocytic
Lymphoma malignant
Intestine small, ileum
Lymphoma malignant lymphocytic
Intestine small, jejunum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Liver
Hamangioma
Hemnngiosarcoma
FIegatoeelIular carcinoma
Flepatacallular adenoma
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Mesentery
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Fat, lymphoma malignant
Pancreas
Lymphoma malignant lymphacytic
Lymphoma malignant
Lymphoma malignant mixed
Salivary glands
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
+
a
+
+
+
.
+
+
+
+
+
.
+
+
+
+
+
-h
+
+
+
+
+
+
+
+
A
+
+
+
+
+
+
-a-
+
+
+
i-
+
+
+
+
+
.
+
.
4
+
+
-i-
+
+
+
+
+
+
.
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
-h
+
+
+
+
+
t
+
+
t
+
+
+
+
i-
+
+
+
+
+
+
+
+
+
i-
+
+
+
t-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
X
Stomach .
Stomach, forestomach
Glandular, lymphoma malignant
lymphacytic
Stomach , glandular
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
~AFLDY~
Heart
Lymphoma malignant lymphocytic
Lymphoma malignant
Epicardium, lymphoma malignant
+
+
+
+
+
+
+
+
+
,
+
+
+
.
+
+
+
.
+
+
+
+
+
.
+
+
+
+
+
+
+
+
a-
+
+
+
+
+
j-
+
+
+
+
+
+
+
+
+
+
t
i-
+
+
+
.
+
+
+
+
+
t
+
+
+
+
+
.
+
.
+
.
+
t
.
i+
-F
+
-F
+
+
+
+
i-
+
-h
.
.
+
+
+
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
+
+
X
+
+
+
+
+
-
.
+
+
+
.
¢
+
.
¢
+
'r
i-
i-
i-
t
+
t
+
1-
t
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
.
.
+
+
+
+
+
+
.
flymphocytic
~S7bI5Z'YdadE`-~`u
Adrenal gland
Capsule, lymphoma malignant
lymphocytic
Capsule, lymphoma malignant
Capsule, lymphoma malignant mixed
Adrenal gland, cortex
Lymphoma malignant lymphocytic
Lymphoma malignant
Adrenal gland, medulla
Pheochromocytoma malignant
Pheochromocytoma benign
Islets, pancreatic
Lymphoma malignant mixed
Parathyroid gland
Pituitary gland
Paa-s distalis, adenoma
Pars distalis, carcinoma
Pars intsrmedia, adenoma
Thyroid gland
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma maligaant mixed
Follicularcell,adeaoma
+
+
+
+
+
.
+
+
+
+
+
+
+
f
+
+
+
+
+.. + . +
+
+
+
.
+
+
+
+
i-
+
+
+
+
t
+
+
+
+
+
-t
+
+
+
+
+
+
+
+
+
h
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
i-
+
-t
+
+
+
+
+
t
+
+
+
+
-a
&L
+
-I- - +
+
+
+
+
M
+
+
i-
+ . +
.+
+
+
+
hS
,
+
+
+
s-
+
+
+
+
M
+
+
I
+
+
M . R3
NE +
+
+
i+
M
+
F!i
.
i4I
+
+
+
_F
+
+
+
t
+
+
+
+
+
.
+
+
+
+
+
.
.
.
+
.
+
M
+
+
+
M
+
.
+
+
.
.
.
Tissue, NOS
Sarcoma, poorly differentiated
205
Hydroquinone,N`PP TR, 366
TABLE I32 . INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : VEHICLE CONTROL
(Continued)
WEEKS
STUDY
N
CARCASS
ID
ALIMENTARY SYSTEM
Esophagus
Gallbladder
Lymphoma malignant mixed
Intestine large
Intestine large, cecum
Lymphoma malignant lympbocytic
Intestine large, colon
Intestine large, rectum
Intestine small
Intestine small, duodenum
Lymphoma malignant lymphocytic
Lymphoma malignant
Intestine small, ileum
Lymphoma malignant lymphocytic
Intestine small, jejunum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Liver
Hemangiorna
Hemangiosarcoma
FTepatocellular careinoma
HepatoceLlularadenoma
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Mesentery
Lymphoma malignant tymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Fat, lymphoma malignant
Pancreas
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
SaIivary glands
Ly mphoma ma lig na nt lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Stomach
Stomach, forestomach
Glandular, lymphoma malignant
hoc
~g
StLymph
. y a~
m mey ul ar
a-"c
malignant
d
lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
CA' 1- ,
Heart
~
ITSTENE--
Lymphoma malignant lymphocytic
1
0
1
0
1
0
1
0
1
0
4
5
4
8
5
1
5
1
5
2
+
+
t
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
s
i
s s
i
a
s s
2
TOTAL:
TISSUES
TUMORS
i
.
.
52
52
53
52
1
1
49
.
.
'
7f
+
+
.
i-
i-
+
+
+
+
+
+
X
+
+
+
+
+
+
-i+
+
+
.
.
.
.
+
+
+
+
.
52
.i
2
55
1
1
1
2
3
2
4
19
3
1
1
1
54
1
I
2
.
-
.
54
3
1
2
54
54
X
1
53
1
1
1
+
55
Y
1
I
+
+
+
f
+
SS
lympltocytic
Capsule, lymphoma malignant
Capsule, lymphoma malignant mixed
Adrenal gland, cortex
Lymphoma malignant lymphocytic
Lymphoma malignant
Adrenal gland, medulla
Phecebromocytoma malignant
Pheochromocytoma benign
Islets, pancreatic
Lymphoma malignant mixed
Parathyroid gland
Pituitary gland
Paxs dista!is, adenoma
Pars distalis, carcinoma
Pars intermedia,
adenoma
Thyroid gland
Lymphoma malignant lymphocytic
,
'
Lymphoma malignant
Epicardium, lymphoma malignant
Flymphocytic
ENDOCRINE SYSTEM
Adrenal gland
Capsule, lymphoma malignant
55
5p
2
53
52
1
+
+
+
+
+
+
+
+
F
M
+
+
+
+
+
+
+
X
+
+
+
+
X
+
.
+
+
X
+
X
+
+
+
+
R
Lymphoma malignant
Lymphoma malignant mixed
F o llicu l ar ce ll , ad eaoma
1
1
55
1
1
51
I
1
51
1
40
52
11
1
1
55
1
1
.
I
3
8HA L 13ODY SYSTEM
Tissue, NOS
Sarcoma, poorly differentiated
Hydroquinone, NTP TR 366,
1
1
206
WEEKS ON
0 0 0 0 0 0 0
STUDY
.
CARCASS
ID
GENITAL SYSTEM
Ovary
HEMATOPOIETIC SYSTEM
Bone marrow
Lymphoma malignant lymphocytic
Lymph node
Lymphoma malignant lymphocytic
Lymphoma malignant
Axillary, lymphoma malignant
Bronchial, 2ymphoma malignant
lymphocytic
Bronchial, lymphoma malignant mixed
Iliac ; lymphoma malignant
Iliac, lymphoma malignant mixed
Inguiaal, lymphoma malignant
Iymphocytic
I¢guinal, lymphoma malignant mixed
Lumbar, lymphoma malignant lymphocytic
Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
Mediastiaal, lymphoma malignant
lymphocytic
Mediastinal, lymphoma malignant
MediasCinal, lymphoma malignant mixed
Pancreatic, lymphoma malignant
lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymph node, mesenteric
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Lymphoma malignant lymphocytic
Lymphoma
Lymphoma
Thymus
Lymphoma
Lymphoma
malignant
malignant mixed
malignant lymphocytic
malignant mixed
INTEGUMENTARY SYSTEM
Mammary gland
Adanocarcinoma
Lymphoma malignant lymphocytic
Skin
Basal cell carcinoma
Subcutaneous tissue, fibmsarcoma
Subcutaneous tissue, lymphoma
malignant lymphocytic
Subcutaneous tissue, lymphoma
malignant
Tail, aeurofibrosarcoma
Bone
NER"US SYSTEM
Brain
Carcinoma, extension, metastatic,
patuitary glaad
Cerehrum, oligodendroglioma malignant
Spinal cord
0 0
9
1
3
1
0 0 0 0 0 1
9
4
9
5
9
7
9
9
9
9
0
0
0
5
0
5
1
1 1 1
0
5
0
5
0
5
0
5
1
1
5
2
4
4
9
5
4
2
4
5
2
3
4
0
4
4
6
2
4
2
3
5
5
0
0
5 .4
4
3
4
4
1
2
4
0
3
4
0
1
4
0
2
4
3
2
4
3
3
4
4
4
4
5
5
3
+
+
+
+
+
f
+
t
+
+
+
+
+
+
6
7
7
1
7
8
.4
5
5
4
6
5
4
1
3
4
8
5
4
3
5
4
4
1
+
+
+
a-
+
+
+
+
%
X
+
+
+
+
+
1
+
+
.
+
+
+
+
-t-
+
t
+
+
.
+
+
0
5
-t-
+
,
;
.
X
X
X
+
+
+
+
+
+
R
X
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-F
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
X
R
X
X
X
.
X
X
Y
X
-
X
X
-
R
X
X
?C
K
+
M
+
+
+
M
.
X
M
.
+
+
Lymphoma malignant
Spleen
8
6
6
2
lpmphocytic
Lymphoma malignant lymphocytic
8
4
5
3
Pancreatic, lymphoma malignant
Pancreatic, lymphoma malignant mixed
- Renal, lymphoma malignant tymphocytic
' Renal, lymphoma malignant
Thoracic, lymphoma malignant
Lymph node, mandibuIar
8
0
5
4
+
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Teratoma
Perinearian tissue, lymphoma
malignant lymphocytic
Periovarian tissue, lymphoma malignant
Periovarian tissue, lymphoma
malignant mixed
Uterus
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Seross, lymphoma malignant
0 0 0
4
2
+
+
+
+
+
+
X
R
+
+
R
X
.
+
.
+
tr
+-
+
M
+
+
.
+
X
+
+
+
+
+
+
+
+
+
+
+
t
+
X
+
iR
+
+
+
X
X
,
+
+
+
+
+
+
+
+
+
-
X
X
X
X
.
+
+
+
+
+
+
.
X
+
+
+
+
+
M
X
X
A
X
X
+ Y +
+
+
X
+
IC
+
A
tJL
M
+
M
4I
M
M
+
R
M
+
+
+
+
M
+
+
+
X
.
+
+
X
+
+
+
X
M
+
X
+
+
+
+
+
i-
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
+
X
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
- ;-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
'
R
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
X
+
207
I
+
I-¬ydrocguinone, NTP'I'R 366
WEEKS
STUDY
CARCASS
ID
GENITAL SYSTEM
Ovarg
Lymphoma malignant Lympbocytic
Lymphoma malignant
Lymphoma malignant mixed
Teratoma
Periovariau tissue, lymphoma
malignant lymphocytic
Periovanaa tissue, lymphoma malignant
Periwariaa tissue, lymphoma
malignant mixed
1
1
1 . 1
0
5
0
5
1
0
5
0
6
0
6
0
6
1
1
0
6
0
6
1
1
1
1
1
1
1
0
6
0
6
1
1
1
1
1
1
6
1
7
3
7
4
8
3
9
3
9
4
0
3
1
4
2
1
2
2
4
3
5
2
7
1
7
2
8
2.
9
1
9
2
0
1
0
2
1
3
2
2
1
1
2
3
3
1
4
2
+
+
+
+
+
+
+
+
+
+
.
+
.
+
+
+
+
+
+
+
+
+
+
. . .
+
+
+
.
M
+
t
-F
.
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
0
5
0
5
0
5
1
1
x
4.
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
+
+
+
+
+
..
+
+
+
+
+
¢
+
+
k
k
+
.
I
~
0
6
-
0
6
0
6
0
6
0
6
0
6
0
6
x
0
6
0
6
malignant
malignant mixed
mesenteric
malignant lympbocytic
malignant
malignant mixed
X
0
6
i
-
SYSTEM
T
Mammary gland
Adenocarcinoma
Lymphoma malignant lymphocytic
Ski n
Basal cell carcinoma
Subcutaneous tissue, fibrosarcoma
Subcutaneous tissue, lymphoma
malignant lymphocytic
Subcutaneous tissue, lymphoma
malignant
Tail, neurofibrosarcoma
Bone
NERNOU
Brain
Carcinoma, extension, metastatic,
pituitary gland
Cerebrum, oligodendroglioma malignant
Spinal cord
FIydrmquinone, NTP TR 366
-
-
X
.
R
.
lymphocytic
-
-
R
.
lympbocytic
Lymph node, mandibvlar
Lymphoma malignant lymphocytic
lymphocytic
mixed
1
;
HEMATOPOIETIC SYSTEM
Bone marrow
Lym homa malignant lymptiocytic
Lymph nods
Lymphoma malignant 3ymphocytic
Lymphoma malignant
Aziliary, lymphoma malignant
Bronchial, lymphoma malignant
lymphocytic
Bronchial, lymphoma malignant mixed
Iliac, lymphoma malignant
Iliac, lymphoma malignant minced
Inguinal, lymphoma malignant
Il'mPhocYtie
Ingniaal, lymphoma malignant mixer
Lumbar, lymphoma malignant lymphocytic
Lumber, lymphoma malignant
Lumbar, lymphoma malignant mixed
Mediastinal, iymphama malignant
lymphocytic
Mediast,inal, lymphoma malignant
Mediastinal, lymphoma malignant mixed
Pancreatic, Lymphoma malignant
lymphocytic
Pancreatic, lymphoma malignant
Pancreatic, lymphoma malignant mixed
Renal, lymphoma malignant tymphocytic
Renal, lymphoma malignant
Thoracic, lymphoma malignant
mixed
1
X
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Berosa, lymphoma malignant
'a,,"
Thymus
ymph
malignant
Lymphoma malignant
Lymphoma
.m. malignant
L
.
Lymphoma malignant
Lymphoma malignant
0
5
'
Uterus
Lymphoma
Lymphoma
Lymph node,
Lymphoma
Lymphoma
Lymphoma
0
5
1
N
X
.
X
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
+
+
+
+
R
+
x
+
+
+
+
X
.+
+
+
X
+
+
+
X
+
+
+
+
X
+
+
X
.
.
.
.
.
.
.
R
.
X
.
.
.
R
.
7°s
.
K
.
.
X
.
.
.
.
X
.
.
.
.
.
X
+
+
+
+
+
+
M
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
.
1VL
.
X
X
.
+
-F
.
+
+
+
+
-a
+
t-
+
+
+
+
+
+
M
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
+
t
+
f
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
-F
+
-F
+
+
+
t
+
+
.
+
t
+
i-
t
.
+
+
209
+
.
+
+
+
+ . +
+
t
+
+
+
+
+
-F
+
.
.
i
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF; FEMALE MICE: VEHICLE CONTROL
(Continued)
WS ON
DY
1
0
6
1
0
6
1
0
6
I
-0
6
1
D
6
CARCASS
IA
4
5
1
4
8
1
5
1
F
5
1
2
5
2
1
+
+
+
+
X
.
TOTAL:
TISSUES
TUMORS
Ovary
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Teratoma
'
Periovariaa tissue, lymphoma.
malignant lymphocytic
Periovadaa tissue, lymphoma malignant
Peaovarian tissue, lymphoma
malignant mixed
Uterus
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Semsa, lymphoma malignant
.
i-
Bone marrow
+
+
+
+
t
+
+
+
+
t
Lymphoma malignant lymphocytic
Lymph node
Lymphoma malignant lymphocytic
'
..
.
.
.
.
.
.
..
.
.
+
+
+
+
.
.
.
.
.
'
.
.
.
1
1
_1
1
X
1
1
-
X
1
2
3
1
"
malignant mixed
malignant lymphocytic
malignant
malignant mixed
malignant lymphocytic
malignant mixed
Mammary gland
Adenocarcinoma
Lymphoma malignant lymphocytic
Skin
Basal cell carcinoma
Subcutaneous tissue, fibrosarcoma
Subcutaneous tissue, lymphoma
malignant lymphocytic
Subcutaneous tissue, lymphoma
malignant
Tail, neurofibmsarcoma
MUSCULOSKEL
Hone
AL SYSTEM
ERVOUS SYSTEM
Brain
Carcinoma, extension, metastatic,
pituitary gla¢d
Cerebrum, oiigodeadroglioma malignant
Spinal eord
.
3
1
2
.
I
4
2-1
Pancreatic, lymphoma malignant
Pancreatic, lymphoma malignant mixed
Renal, lymphoma malig . lymphocytic
Renal, lymphoma malignant
Thoracic, lymphoma malignant
Lymphoma
Spleen
Lymphoma
Lymphoma
Lymphoma
Thymus
Lymphoma
Lymphoma
1
55
1
.
Lumbar, lymphoma mafig. lymphocytic
Lumbar, lymphoma malignant
Lumbar, lympboma malignant mixed
riiediastinal, lymphoma malignant
lymphocytic
Mediastinal, lymphoma malignant
Mediastinal, lymphoma malig . mixed
Pancreatic, lymphoma malignant
Lymphoma malignant lymphocytic
Lymphoma malignant
55
1
lymphocytic
Inguinal, lymphoma malignant mixed
mandibular
malignant lymphocytic
malignant
malignant mixed
mesenteric
3
1
1
Bronchial, lymphoma malignant
lymphocytic
Bronchial, lymphoma malignant mixed
Iliac, lymphoma malignant
Iliac, lymphoma malignant mixed
Inguinal, lymphoma malignant
lymphocytic
.
55
2
1
1
1 '
2
54
2
2
1
+
.
,
.
Axillary, lymphoma malign ant
Lymph node,
Lymphoma
Lymphoma
Lymphoma
Lymph node,
- .
.
Lymphoma malignant
lymphocytic
-
+
.
+
+
+
M
M
-
+
~
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
+
X
h
i-
i-
1
+
7{
50
6
2
2
52
+
%
11
3
5
55
10
3
7
44
4
3
.
-
"
62
3
55
1
1-
X
+
+
-1-
+
+
55
+
+
+
+
+
55
4
209
I-iydraquirlone, IVTP TR 366
CONTROL
PATHOLOGY OF FEMALE MICE : VEHICLE
TABLE I)2 . INDIVIDUAL ANIMAL TUMOR
(Continued)
WEEKS
STUDY
N
-
CARCASS
ID '
.
.
.
_
Lung
Alveolarfbronchiolaradenoma
AlveolarPoronchiolar carcinoma
Basal cell carcinoma, metastatic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lrmphoma malignant mixed
Pleura, lymphoma malignant lymphocytic
Nose
.
Trachea
Lymphoma malignant mixed .
00
4
5
2 4
S
5
6
5
+
0
6
2
0
6
7
0
7
1
0
7
8
0
8
0
0
8
4
0
8
6
0
3
1
0
9
1
0
9
4
0
9
5
0
9
7
00
9 9
9 9
1
0
0
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
5
8
5
3
5
4
1
2
4
9
5
2
4
2
3
0
4
6
2
2
3
0
5
0
4
3
4
0
3
0
1
0
2
3
2
3
3
4
4
4
5
5
3
+
+
+
+
K
+
i-
+
R
X
+
+
+
+
+
+
+
A
0
5
8
+
+
+
+
+
+
+
+
+
+
X+
+
.
..
M
+
+
+
+
+
+
+
+
+
_
+
+
.
+
.
+
+
.
.
+
+
+
+
+
+
+
+
+
X
. ,
.
+
+
+
+
+
-F
+
+
.
x
Adenoma
Lymphoma malignant mixed
+
+
++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
i-
+
+
+
X .
X
X
Lymphoma malignant mixed
xyaroquinone, NTP TR 366
++
.
Harderian gland
Capsule, lymphoma malignant
lymphocytic
Fat, lymphoma malignant mixed
Renal Cubule,adenoma
Urinary bladder
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
.
t.
+
¢
+
+
X
.
,
Ear
Canal, external ear, squamous cell
carcinoma
'
Eye
Kidney
Lymphoma malignant 3ymphocytic
Lymphoma malignant
.
X
. .
+
+
+
+
.
R
+
+
+
1
2
,
M
+
+
_
.
X
+
+
+
+
.
a
+
+
+
+
+
+
+
.
210
+
+
+
~
+
+
+
+
.
+
+
+
.
.
..
.
.
, '
.
.
.
~
:
.
,
1
i
~
~
~
.
.
.
TABLE D2 . INDIVIDUAL ANIMAL TUMOR PA'FAC9L.CDG% OF FEMALE MICE :' VEHICLE CON'PROL
(Continued)
WEEKS N
STUDY .
CARCASS
ID
.
ESPIRATORY SYSTEM
Lung
tllveolarlbronchiolar adenoma
Alveolar/bronchiolar carcinoma
Basal cell carcinoma, metastatic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Pleura, lymphoma malignant lymphocytic
Nose
Trachea
Lymphoma malignant mixed
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
0
5
1
0
6
I
0
6
1
0
6
I
0
6
2
0
6
1
0
6
I
0
6
7.
0
6
I
0
6
1
4
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
4
6
2
4
7
3
4
7
4
4
8
3
4
9
3
4
9
4
5
0
3
5
1
4
4
2
1
4
2
2
4
4
3
4
5
2
4
7
1
4
7
2
4
8
2
4
9
1
4
9
2
5
0
1
5
0
2
5
1
3
5
2
2
4
1
1
4
1
3
4
3
1
4
4
2
+
+.
+
+
+
+
+
+
+
+
+
r
+
+
+
+
tr
X
+
+
+
+
+
+
+
+
+
+
t
+
+
+
+
+
-~
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
R
X
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
SPECIAL SENSES SYSTEM
Ear
Canal, external ear, squamous cell
carcinom a
Eye
Harderian gland
Adenoma
Lymphoma malignant mixed
Kidney
Lymphoma malignant tymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Capsule, lymphoma malignant
lymphocytic
Fat, lympfioma malignant mixed
Renaltubute,adenoma
Urinary bladder
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
+
+
X
+
+
+
+
+
+
}C
Y
+
+
+
+
+
+
+
+
X
+
+
.
+
+
.
+
+
.
X
+
+
+
+
+
+
X
+
+
+
M
+
+
+
+
+
+
+
X
X
t
¢
i-
+
+
+
+
+
X
+
+
X
.
211
+
-
Iiydroquinone, IVTP TR 366
"
TABLE D2 . INDIVIDUAL AIIIIYSAIa °I°iTMC318, PATHOLOGY OF FEMALE MICE: VEHICLE CONTROL
(Continued)
CARCASS
ID
..
Luag
Alveolarlbroachioiar adenoma
Alveolar/bronchiolar carcinoma
Basal cell carcinoma, metastatic
Lymphoma malignant lymphocytic .
Lymphoma malignant
Lymphoma malignant mixed Pleura, lymphoma malig. lymphocytic
Nose
Trachea
Lymphoma malignant mixed
.
.
Y
PE 7A.[.
Ear
Canal, external ear, sqnamous cell
carcinoma
Eye
Harderian gland
Adenoma
Lymphoma malignant mixed
I{idney
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Capsule, lymphoma malignant
lymphocytic
Fat, lymphoma malignant mixed
Renal tubule, adenoma
Urinary bladder
Lymphoma malignant lympbocytic
Lymphoma malignant
0
s
0
s
0
s
0
s
0
s
5
1
8
1
1
1
1
2
2
1
+
+
+
+
+
X
+
+
+
+
55
3
1
I
4
3
2
1
54
54
1
%
+
+
+
+
+
+
1
+
1
2
3
2
1
X
,
+
+
+
+
I
+
55
2
2
1
1
1
+
+
+
+
53
4
1
1
+
X
Lymphoma malignant mixed
Hydroquinone, NTP TR 366
M
TABLE d)2 . INDIVIDUAL : ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE 'I'R'O-YEAR
GAVelGE STUDY OF I-IYI.AROQLIiNONEc LOW DOSE
-
WEEKS O N
0
0
0
0
0
0
0
0
0
0
0
0
0
9
6
0
3
0
3
0
5
0
5
0
5
1
1
0
5
0
5
1
1
1
1
1
1
CARCASS
TD
5
3
5
6,
3
6
5
9
4
5
5
5
6
4
4
6
0
5
5
5
1
6
5
5
6
4
3
5
8
5
6
1
5
6
3
3
5
6
4
6
0
4
5
8
4
5
8
3
5
4
4
5
5
4
5
7
1
,
7
2
7
3
8
1
8
2
9
1
9
2
+
+
+
+
+
M
+
+
+
M
+
+
+
+
+
A
+
+
+
+
+
+
+
+
+
+
+
A
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
R
+
+
+
+
+
+
+
-F
+
+
+
+
+
Pvi
+
+
A
+
+
+
+
M
+
+
+
+
+
+
+
+
+
+
+
°
+
+
+
+
+
+
+
+
+
+
+
+
+
+~
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
A
+
+
+
R
+
+
+
X.
+
+
+
+
+
+
+
X
A
+
+
+
-F
+
+ ,+
+
+
.
+
+
+
+
+
.. .
+
R
i-
t
+
+
+
STUDY
ALIMENTARY SYSTEM
Esophags
Grdllbladder
Lymphoma malignant tymphocytic
Intestine large
Intestine large, cecum
Intestine large, colon
Lymphoma malignant lymphocytic
Intestine large, rectum
Intestine small
Intestine small, duodenum
Semsa, fibrosarcoma, meEastatic,
mesentery
Intestine small, ileum
Lymphoma malignant Iymphocytic
Jejunum, lymphoma malignant mixed
Intestine small,jejunum
Lymphoma malignant lymphocytic .
Liver
Choiangiocarcinoma, meYastatic
Aemangioma
5
9
.
.
'
~
7
7
6
3
+
X
+
.
.
Flepatocellulai carcinoma
F£epatocelfularadenoma
Hepatocetlular adenoma, multiple
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
X
9 . 9
2
0
9
9
..
-F
%
Serosa, lymphoma malignant lymphocytic
Stomach, forestomach
Papilloma squamous
Stomach, glandular
CARDIOVASCULAR SYSTEM
Heart
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
9
6
A
A
t
9
6
'+
+
-F
Y
+
+
+
i-
X
%
+
+
+
+
X
+
X
X
+
+
+
+
X
+
+
~f-
+
f
1
R
A
+
9
8
+
+
~tX
+
+
+
+
+
+
+
+
+
+
+
+
-h
+
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
R
+
X
A
7C
+
X
M
+
X
+
+
}C
R
1
+
+
+
a-
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
X
+
i-
X
X
+
0
5
0
5
0
5
0
5
°
.
.
+
+
t
X
%
R
%
+
+
X
0
5
+
"
+
.
+
+
+
%
X
]I
-F
X
+
1
X
'
matastatic, mesentery
Lymphoma malignant tymphocytic
5alivary glands
Lymphoma mal:gnant lymphocytic
Lymphoma malignant
Stomach
9
5
X
Mesentery
Cholangiacarcinoma, metasCatic
Fibrosarcoma
Fibrosarcoma, multiple
Lymphoma malignant lymphocytic
Paacreas
Fibrosarcoma, early invasion,
8
7
9
1
-I-
+
R
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
M
M
+
+
M
+
1i+
+
+
+
X
ENDOCRINE SYSTEM
Capsule, cholangiocarcinoma, metastatie
Capsule,
lymph lymphoma malignant
ocytic
Adrenal gland, cortex
Lymphoma malignant mixed
Adrenal gland, medulla
Islets, pancreatic
Parathyroid gland
Pituitary gland.
Pan distalis, adenoma
Pars distatis, carcinoma
Thyroid gland
Lymphoma malignant
X
-F
X
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
P/!
+
+
+
+
+
+
+
+
+
+
+
+
t
X
+
+
+
+
+
M
+
X
+
+
+
+
X
M
+
+
M
M
A
+
+
+
+
+
i-
+
+
+
Follicular cell,adenoma
None
+
X
+
+
+
+
+
X
.
_
+
+
+
R
+
X
+
+
+
+
I{
+
X
+
+
X
+
X
SYSTEM
213
F-Tydroquinone, NTP TR 366
TABLE D2 . INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : LOW DOSE
(Continued)
WEEKS ON
STUDY
.
CARCASS
ID
M~i-Esnph~~~s
Gal7bladder
Lymphoma malignant lymphocytic
Intestine large
Intestine large, cecum
Intestine large, colon
Lymphoma malignant lymphocytic
Intestine large, rectum
Intestine small
Intestine small, duodenum
Serosa, fibrosarcoma, metastatic,
mesentery
Intestine small, ileum
Lymphoma malignant lymphocytic
Jejunum, lymphoma malignant mixed
Intestine small, jejunum
Lymphoma malignant lymphocytic
Liver
Cholaagiocarcinoma, matastatic
Hemaagioma
Hepatocallular carcinoma
HepaEocellularadenoma
Hepatocellular adenoma, multiple
Lymphoma malignant histiocytic
I
0
j 5
1
0
5
1
0
5
1
0
5
I
0
5
1
0
5
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
I
0
6
I
0
6
1
1
0
0
6 . .6
1
0
6
1
0
6
2
0
6
5
9
3
6
0
3
6
1
4
6
2
5
6
5
3
6
5
4
5
3
1
5
4
3
5
3
6
3
0
2
0
2
1
3
2
2
2
3
2
4
4
2
5
2
4
2
5
2
6
1
6
2
1
1
1
2
+
+
+
+
.
-~-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
%
X
X
X
-
+
+
+
f
Mesentery
Cholangiocarciroma, metastatic
Fibmsarcoma
Fibrosareoma, multiple
Lymphoma malignant tymphocytic
X
+
+
%
X
'
-
+
.
.
Pancreas
Fibrosanroma, early invasion,
metastatic, mesentery
Lympboma malignant lymphocytic
+
.
R
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant lymphocytic
1
0
6
.
g
Lymphoma malignant tymphocytic
Salivary glaads
4
1
1. . 1
0
0
. 6
6
+
.
+
+
+
-I-
+
Lymphoma malignant
Stomach
Serosa, lymphoma malignant lymphocytic
Stomach, forestomach
Papitloma squamous
Stomach, glandular
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
.
+
+
+
-h
+
i-
+
+
+
-
+
-
+
,y
+
+
CARDIOVASCULAR SYSTEM
Heart
Lymphoma malignant lymphocytic
+
Lymphoma malignant
Lymphoma malignant mixed
ENDOCRINE SYSTZM--Adrenal gland
Capsule, cholangiocarcinoma, metastatic Capsule, lymphoma malignant
lymphocytic
Adrenal gland, cortex
Lympboma malignant mixed
Adrenal gland, medulla
Islets, pancreatic
Parathyroid gland
Pituitary gland
Pars distalis, adenoma
Pars distalis, carcinoma
Thyroid gland
Lymphoma malignant
Follicular cell, adenoma
+
+
+
X
+
X
+
+
+
+
+
R
+
R
+
7L
+
X
-F
X
+
+
+
+
+
+
+
+
+
+
+
+
IC
GENERAL BODY sysTEm
None
Hydroquinone, NTP TIZ 366
+
214
+
X
+
+
+
X
+
+
R
r~
. .~t._ :.
t .. . ..
;
.
.
.. ,
~
.
.
~
.
.
.
.
~
.
_
~
.
..
.
.
.
.
TABLE D2 . INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : LOW DOSE
(Continued)
WEEK ON
STUDY
1
Q
6
1
0
B
1
0
6
1
0
6
1
0
6
CARCASS
ID
6
2
1
6
3
1
6
3
2
9
d
1
6
5
1
TOTAL:
TISSUES
TUMORS
ALIMENTARY SYSTEM
Galtbladdee
Lymphoma malignant lymphocytic
Intestine large
Intestine large, cecum.
,
Intestine large,colon
Lymphoma malignant lymphocytic
Intestine large, rectum
Intestine small
Intestine small, duodenum
Serosa, flbrosareoma, metastatic,
mesentery
Intestine smalt, ileum
Lymphoma
small
malignant
jejunumlymphocytic
Jejunum, lymphoma malignant mixed
Intestine
Lympbom.3 malignant lymphocytic
Liver
Cholangiocarcinoma, metastatic
Heenangioma
HepatocelluLar carcinoma
Hepatocellular adenoma
Hepatocallular adenoma, multiple
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Mesentery
Cholangicearcinoma, metastatic
Fibrosarcoma
Fibrosarcoma, multiple
Lymphoma malignant lymphocytic
Pancreas
Fibrosarcama, early invasion,
metastaCic, me seatery
Lymphoma malignant lymphocytic
Salivary glands
Lymphoma malignant lympkocytic
12
7,
gs
13
14
Z
14
16
15
,
.
.
+
+-
+
+
.
'
i-
.
.
.
.
+
+
+
+
.
+
Lymphoma malignant
Stomach, focastomach
Papiiloma squamous
Stomach, glandular
1
.
17
1
16
_
CARDIOVASCULAR
Heart
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant
Follicular call, adenoma
2
54
2
17
Serosa, lymphoma malig. lymphocytic
Thyroid gland
_
1
Stomach
ENDOCRINE SYSTEM
Adrenal gland
Capsule, cholangiocarcinoma, metastatic
Capsule, lymphoma malignant
lymphocytic
Adrenal gland, cortex
Lymphoma malignant mixed
Adrenal gland, medulla
Islets, pancreatic
Parathyroid gland
Pituitary gland
Pars distalis, adenoma
Pars distalis, carcinoma
1
14
2
1
12
1
55
1
. 1
2
11
4
1
4
1
2
12
1
1
I
2
16
,
_
17
1
1
1
13
1
M
+
1
13
1
11
15
13
29
14
2
+
+
+
+
+
'
ss
t
5
GENERAL BODY SYSTEM
None
215
Hytiroquanone, NTP TR, 366
.
TABLE D2. ' INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : LOW DOSE
(Continued)
0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1-1
WEEKS ON
STUDY
CARCASS
ID
GENITAL SYSTEM
Clitoral gland
Ovary
Adenoma
Lymphoma malignant lymphocytic
Lymphoma malignant
Osteosarcoma, metastatic, bona
uterus
5
9
6
3
7
7
8
1
8
7
8
8
9
0
9
2
9
5
9
6
9-. , 9
8
8
9
8
0
3
0
.3
0
5
0
5
0
5
0
5
0
5
0
5
0
5
0
5
1
1
1
3
5
3
5
9
4
5
5
4
4
0
5
5
1
5
5
4
3
8
5
1
5
3
3
6
4.
0
4
8
4
8
3
4
4
5
4
7
1
7
2
7
3
8
1
8
2
9
2
9
2
+
+
+
+
M
+
+
+
+
+
+
-t-
+
+
+
f
+
+
+
+
+
X
"
+
i-
+
+
+
+
+
+
°
.
lymphocyCic
Bronchial, lymphoma malignant
lymphocytic
Bronchial, lymphoma malignant mixed
Deep cervical, lymphoma malignant
mixed
Iliac, lymphoma malignant lymphocytic
Iliac, lymphoma malignant
Iliac, lympHoma malignant mixed
I i inhl, lymphoma malignant
+
+
+
+
+
+
+
+
Lymphoma malignant mixed
Capsule, cholangiocarcinoma, metastatic
Thymus
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Mammary gland
Adenocarcinoma
Cholangiocarcinoma, metastatic,
multiple
Lymphoma malignant lymphocytic
Lymphoma malignant
Thoracic, hepatoce llu l ar carcinoma,
metastatie, liver
Skin
Subcutaneous tissue,fibrosarcoma
Subcutaneous tissue,hapatocellular
carcinoma, metastatic, liver
Subcutaneous tissue, lymphoma
malignant lymphocytic
MLT5t;T7L~7
Bone
Lumbar, vertebra, osteosarcoma
Vertebra, cholangiocarcinoma,
IS12C25C3EYC
Skeletal muscle
Abdominal, fibrosarcoma, early
Hydroquinone, NTP TR 366
.
+
+
+
+
+
+
+
X
A
+
+
+
+
+
+
+
+
+
+
+
+
+
X
R
K
j
-
7L
X
R
:>
r
+
+
+
+
-F
+
+
R
+
+
A
+
X
+
+
+
+
+
~
+
+
+
+
+
+
+
X
+
+
X
+
X
M
PR
+
+
+
X
+
+
+
'
+
R
+
+
+
+
.
-1-
+
+
+
+
+
+
bf
+
M
X
+
+
rii
+
lYl
+
X
+
+
X
+
X
+
+
+
+
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
+
X
+
R
+
M
A
+
X
+
X
+
+
%
R
+
-F
+
+
+
+
+
.
+
+
+
+
+
+
R
+
+
+
+
+
+
+
+
+. +
+
+
A
+
+
+
.
+
invasion, metastatic, mesentery
Abdominal, diaphragm,
cholangiocarcinoma, metastatic
+
A.
Lymphoma malignant
Lymphoma malignant mixed
.
Lymph node, mesenteric
Lymphoma malignant lymphocytic
.
Lymphoma malignant
Lymphoma malignant mixed
Renal, cholangiocarcinoma, metastatic
Spleen
. Lymphoma malignant lymphocytic
Lymphoma malignant
+
0
5
'
1
F
Bone marrow
Lymph node
Axiilary, lymphoma malignant
Lumbar lymphoma malignant lymphocytic
Lumbar,
Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
Lumbar, osteosarcoma, metastaCic, bone
Mediastinal, lymphoma malignant
lymphocytic
Mediastinal, lymphoma malignant
Mediastinat, lymphoma malignant mixed
Popliteal, lymphoma malignant
lymphocytic
Renal, lymphoma malignant lymphocytic
Lymph node, mandibular
Lymphoma malignant lymphocytic
+
+ + + +
+ + + + + + + + + + + ,
4
Hemangioma
Lymphoma malignant lymphocytic
Polyp stromal
x , X
X
+
1
X
216
+
+
_
0
5
+ +
TABLE L?2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : LOW DOSE
(Continued)
WEEKS ON
STUDY
1
1
1
0
5
0
5
0
5
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
6
0
6
0
6
0
6
9
3
0
3
1
4
2
5
5
3
5
4
3
1
4
3
5
3
6
3
0
1
0
2
1
3
2
2
2
3
2
4
4
2
5
2
4
1
4
2
5
2
6
1
6
2
1
1
1
2
-f-
,-
+
+
+
+
+
i-
+
+
i-
+
+
M
+
+
+
+
+
+
+
+
+
+
+
6
5
CARCASS
TD
GENITAL SYSTEM
Clitoral gland
Ovary
Adenoma
0
5
1
+
0
5
0
6
+
Lymphoma malignant lymphocytic
,
Lymphoma malignant
Os-teosarcoma, metastatic, bone
Uterus
Hemangioma
Lymphoma malignant lymphocytic
0
6
.
.
0
6
0
6
-
0
6
+
.
.
0
6
0
6
0
6
0
6
0
6
g
g
.
+
.
0
6
..
0
6
0
6
.
0
6
0
6
1
1
1
,
.
+
+
+
Polyp stromat
~Y~FII
'IC SYSTEM
Bone marrow
Lymphnode
.
Axillary, lymphoma malignant
.
.
.
.
.
i- . .-.
lymphocytic
Bronchial, lymphoma malignant
lymphocytic
Bronchial, lymphoma malignant mixed
Deep cerv ical, lymphama malignant
mixed
Iliac, lymphoma malignant lymphocytic
Iliac, lymphoma malignant
Iliac, lymphoma malignant mixed
Inguinal, lymphoma malignant
lympkocytic
Lumbar, lymphoma malignant lymphocytic
Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
Lumbar, osteosarcoma, metastatic, bone
Medias4inal, lymphoma malignant
lymphocytic
Mediastinal, lymphoma malignant
Mediastinal, lymphoma malignant mixed
Popliteal, lymphoma malignant
..
+
+
.
.
.
.
g
lympbocyCic
Renal, lymphoma malignant lymphocytic
Lymph node, maadibulaz
.
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymph node, mesenteric
-
Lymphoma malignant lymphocytic
-
.
Lymphoma malignant
Lymphoma malignant mixed
Renal, cholangiocarcinoma, metastatic
Spleen
+
Lymphoma malignant lycuphocytic
Lymphoma malignant
+
Y
Lymphoma malignant mixed
Capsule, cholangiocarcinoma, metastatic
Thymus
Lymphoma malignant lymphocytic
+
+
X
X
Lymphoma malignant
Lymphoma malignant mixed
--
INTEGUMFNTARY SYSTEM
Mammary gland
Adouocarcinoma
Cholangiocantinoma, meEastatic, .
multiple
Lymphoma malignant lymphocytic
Lymphoma malignant
Thoracic, hepatocellular carcinoma,
metastatic, liver
Skin
Subcutaneous tissue, fibrosarcoma
Subcutaneous tissue, hepatocellular
carcinoma, metastatic, liver
Subcutaneous tissue, lymphoma
malignant lymghocytic
+
%
+
Y
+
X
.
+
X
.
.
.
,
USCULOSKELETAL SYSTEM
Bone
Lumbar, vertebra, osteosarcnma
Vertebra, cholangiocarcinoma,
metastaCic
Skeletal muscle
Abdominal, fibmsareoma, early
invasion, metastatic, mesentery
Abdominal, diaphragm,
cholangiocarciaoma, metastatie
.
217
Hydroquinone, NTP TR 366
TABLE D2 . INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : LOW DOSE
(Continued)
WEEKS
STUDY
N
CARCASS
ID
.
Clitorai gland
Ovary
Adenoma
Lymphoma malignant lymphocytic
Lymphoma malignant
Osteosarcoma, metastatic, bone
Uterus
Tiemaagioma ,
Lymphoma malignant lymphocytic
Polyp stromal
I
0
6
1
0
6
1
0
6
1
G
6
1
0
6
9
2
1
6
3
1
6 -ii
3
<I
2
3.
5
1
+
+
+
+
<
+
+
TOTAL:
TISSUES
TUMORS
29
HEMATOP
Bo ne marrow
Lymph node
Axillary, lymphoma malignant
fymphocytic
Bronchial, lymphoma malignant
lymphocytic
Bronchial, lymphoena malignant mixed
Deep cervical, lymghoma malignant
mixed
Iliac, lymphoma malignant lymphocytic
Iliac, lymphoma malignant
Iliac, lymphoma malignant mixed
Inguinal, iymphoma malignant
lymphocytic
Lumbar, lymphoma mal:g .lymphocytic
Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
Lumbar, osteosarcoma, metastatic, bone
Mediastinal, lymphoma malignant
lymphocytic
Mediastinal, lymphoma malignant Mediastiual, lymphoma malig. mixed
Popliteal, lymphoma malignant
lymphocytic
Renal, lymphoma malig .lymphocytic
Lymph node, mandibular
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
_
16
22
.
,
.
1
Z
.
.
,
2
i
, 2
16
17
Lymph-ode, mesenteric
Lymphoma maligaant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Renal, cbolangiocarcinoma, metastatic
Spleen
Lympboma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Capsule ; cholangiocarcinoma, metastatic
Thymus
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
53
.
+
22
.
X
Mammary gland
Adenocareinoma
Cholangiocarcinoma, metastatic,
multiple
Lymphoma malignant lymphocytic
Lymphoma malignant
Thoracic, bepatoce llvlar carcinoma,
metastatic, liver
Skin
Subcutaneous tissue, fibrosarcoma
Subcutaneous tissue, hepatocellular
carcinoma, metastatic, liver
Subcutaneous tissue, lymphoma
malignant IymphocyCic
13
20
2
16
,
_
FRUS-
16
Bone
Lumbar, vertebra, osteosarcoma
Vertebra, cholangiocarcinoma,
meEastatic
Skeletal muscle
Abdominal, frbrosarcama, early
invasion, metastatic, mesentery
Abdominal, diaphragm,
cholangiocarcinoma, metastatic
Hydraqaainone, leTTP TR 366
218
TABLE D2m INDIVIDUAL ANIMAL TUMOR PATHOLOGY (2F FEMALE MICE- LOW DOSE
(Continued)
WEEKS O N
STUDY
0
5
.
.
.
CARCASS
YD
NERVOUS SYSTEM
Brain
Carcinoma, extension, metastatic,
pituitary gland
Lymphoma malignant lymphocytic
Perivascular, lymphoma malignant
lymp"ocytic
Perivascular, lymphoma malignant
Spinalcord
SYSTEM
Lung
Alveolar%bronchiolar adenoma
Fdepatocellular carcinoma, metastatic,
0
6
0
7
0
9
0
8
0
9
0
9
0
9
0
9
0
9
0
9
0
9
0
9
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
-Z--8
3
3
5
5
5
9
4
5
5
5
6
4
4
90
5
5
5
1
6
5
5
6
4
3
5
8
5
6
1
5
6
3
3
-5
6
4
6
0
4
5
8
4
5
8
3
5
4
4
5
5
4
5
7
1
5
7
2
5
7
3
5
8
1
5
8
2
5
3
1
5
9
2
+
+
+
+
t
t
+
t
+
+
r
+
.
X
+
+
+
9
t
3
7
+
1
+
7
,
-
i-
0
+
+
+
+
+
+
X
+
+
+
+
{-
+
i-
+
+
+
X
+
+
5
6
6
8
8
+
+
+
+
i-
i-
3
5
5
5
5
5
5
5
5
5
5
.
X
+
+
X
3
X
.
X
liver
Lymphoma malignant lymphceytic
-Lymphoma malignant
Osteosarcoaia, metastatic, bone
Nose
Trachea
2
X
.
+
8
+
.
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
+
.
-F
'§'
.
'F'
'f'
+
+
+
+
+
+
+
+
+
+
R
+
+
+
+
+
+
t
+
i-
.
$PE~
Harderian gland
Adenoma
URINARY SYSTrM
Kidney
Hepatocellular carcinoma, matastatic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Ostaosarcoma, metasta2ic, bone
Capsule, cholangiocarcinoma, metastatic
Urinary bladder
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
-I-
-0-
X
X
+
X
-i-
X
+
X
X
X
X
X
+
M
+
+
X
+
%
219
+
X
+
+
X
Hydroquinoney NTP TR 366 .
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : LOW DOSE
(Continiaed)
WEEKS
STUDY
P7
CARCASS
NERVOUS
Brain
Carcinoma, extension, metastatic,
pituitary gland
Lymphoma malignant lymphocytic
Perivascular, lymphoma malignant
lymphocytic
Perivascular, lymphoma malignant
Spinal cord
,
Harderian gland
Adenoma
1
0
5
1
0
5
1
0
5
1
0
5
4
0
5
1
0
6
1
0
6
2
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
6
1
0
8
1
0
6
1
0
6
1
0
6
1
0
6
1'
0
6
1
0
6
1
1
0
0
8 ; 6
1
0
B
S
s
D
3
1
4
2
5
5
3
5
4
3
1
4
3
5
3
6
3
0
1
0
2
1
3
2
2
2
3
2
4
4
2
5
2
4
1
4
2
5
2
6
1
6
2.
1
2
.
RESPIRATORT-MT ERLung
Alveolar/bronchiolar adeaoma
Hepatocellular carcinoma, metastatic,
liner
Lymphoma malignant lymphocytic
Lymphoma malignant
Osteosarcoma, metastatic, bone
Nose
Tracbsa
1
0
u
"
'
+
+
2
1
.
+
+
+
+
+
+
.
+
.
+
+
.
+
+
+
X
-
.
+
-F
+
+
-
+
+
+
i-
+
-
f
URINARY SYSTEM
Kidney
Hepatocsllular carcinoma, meCastatic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Osteosarcoma, matastatic, bona
Capsule, cholangiocarcinoma, metastatic
Urinary bladder
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
F-Iydraquanorae, NTP TR 366
3
.
.
220
.
.
TABLE Y32 . INDIVIDUAL A NIMAL TUMOR PATHOLOGY OF
FEMALE MICE : LOW DOSE
(Continued)
Li 1 1 1WEEKS
STUDY
CARCASS
ID
0
6
0
6
U
6
0
6
0
S
2
1
3
1
3
2
4
1
5
1
TOTAL:
TISSUES
TUMORS
,
Brain
Carcinoma, extension, metastatic,
16
pituitary gland
Lymphoma malignant lymphocytic
Perivascular, lymphoma malignant
lymphocytic
Pedvascular,lymphoma malignant
Spinaicord
Lun~
AtaeotarJbmnchioiar adenoma
Hepatocellular carcinoma, metastatiq
liver
Lymphoma malignant lymphocytic
Lymphoma malignant
Osteosarcoma, matastatic, bone
Nose
Trachea
Harderiaa gland
Adenoma.
xiaa9y
.
.
+
t
i-
+
1
.
"
'
2
+
.
.
.
55
6
12
'
16
16
3
2
X
m
fs
Hepatacellular carcinoma, metastatic
Lympboms malignant lymphocyt'sc
Lymphoma malignant
.
Lymphoma malignant mixed
Ostoosarcoma, metastatic, bone
Capsule, cho[angiocarcinoma, metastatic
Urinary bladder
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
.
1
15
1
i
221
Hya3rocguinone, NTP'I`R 366
FEMALE MICE IN THE TWO-YEAR
TABLE D2 . INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF
Gt4VAGE STUDY OF HYDItOQUIIVONE: HIGH DOSE
0 1 0 0 0 0 0 0 0 a9 09 09 09 09 09 10 0 0 0 0 0 0 0
wEExs rr
STUDY
CARCASS
ID
E
f
Y
I
s
;o
Z lld'.'
testine large
.
testiae large, cecum
Lymphoma malignant lymphocytic
Lymphoma maligaant
I Ltestine large, colon
T Ltastine large, rectum
I itestine small
I itestine small, duodenum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
7 itestine small, ileum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
7 ntestine small, jejuaum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
.
,iver
Hepatocellular carcinoma
Stomach, glandular
Lymphoma malignant
Tooth
7
9
8
1
8
9
2
2
4
4
6
8
0
1
3
5
5
.5
5
5
2-_'t
5
2
2
3
2
4
0
1
8
5
0
3
6
5
7
4
8
3
7
3
6
4
3
5
5
3
7
4
6
4
8
2
9
4
8
2
S
3
8
4
8
5
9
3
+
.
+
-r
'
+
.
+
+
+
.
+
.
+
.
-t-t-
+
.
.
+
+
+
'+
+
+
.
+
+
+
.
+
-i+
.
+
+
+
.
A
+
+
.
+
+
+
.
+
+
+
.
A
+
+
.
+
+
t
.
M
A
A
.
+
+
+
.
+
+
+
.
+
+
+
.
M
+
+
.
+
+
+
.
+
+
+
.
+ .
+
+
+ +
aM M M
+ + +
+
+
+
.
+
+
+
+
+
+
+
A
+
A
-h
+
+
+ ' +
+
+
+
+
+
A
+
x
+
+
+
+
R
i
+
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
+
i-
+
-F
+
+
+
.
+
+
+
+
+
+
i.
+
+
M
+
+
+
+
-4-
+
+
-F
+
+
-I.
A
A
.
+
+
.
+
+
A
+
+
+
+
+
,
+
+
+
+
+
.
+
+
t1
A
+
+
+
+
A
-F
+
+
A
A
+
+
-h
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
i-
f
+
-F
+
t
+
+
+
t
+
+
+
+
+
.
+
+
+
+
+
+
T
+
+
+
x
+
A
+
X
A
+
+
+
+
+
+
i-
+
+
+
+
X
+
A
+
X
A
+
+
+
+
+
+
+
+
+
+
+
+
-F
+
+
+
+
X
7L
+
+
+
X
Y
+
R
X
X
.
+
X
+
A
+
+
+
+
+
+
+
M
+
+
+
+
+
+
+
t
+
+
i+
+
+
+
+
+
+
+
+
+
+
t
+
+
t
+
+
t
+
+
+
+
+
+
X
+
+
A
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
-h
+
+
+
+
+
~
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
t
+
+
+
+
X
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
M
.
+
.
.
.
+
.
.
.
+
.
.
.
+
.
M
.
+
.
M
.
¢
.
M
.
+
.
+
.
+
.
+
.
R
M
.
M
.
+
.
.
.
+
.
.
.
+
.
.
.
M
A
.
.
.
M
.
.
X
.
M
.
.
.
.
M
.
X
.
.
+
.
.
.
M
.
.
.
+
.
X
.
.
+
.
.
.
M
.
.
.
M
M
.
+
+
+
+
X
+
+
-r
.
a-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Heart '
Pericardium, lymphoma malignant
undifferenCiated cell type
t
Adrenal gland
Adrenal gland, cortez
Lymphoma malignant
Lymphome malignant uadifferentia4ed
cell type
Adrenal gland, medulla
yru
ry
an ._
g,
atic
gl
7
d tic
md.
Pitm2ap
d
i'ars distalis, adeno~a
Pars intermedia, adenoma
Thyroid gIand
Follicuiarcell,adenoma
Follicular mll, carcinoma
+
+
+
+
+
+
+
.
+
.
+
.
M
.
+
-o~
-r
.
.
X
X
+
Tissue, NOS
Hydroquinone, N'I'F'TR 366
.
R
.
+
X
+
+
+
+
+
X
+
+
+
+
+
A
X
+
+
+
r
.F .
.
2
5
6
.
Stomach
Stomach , fornstomach
1
2
0
.
Pancreas
~ Lymphoma malignant lymphocytic
Salivary glands
Histiocytic sarcoma
Lymphoma malignant lymphocytic
0
5
0
3
Aepatocellular adenoma
Hepatocellnlar adenoma, multiple
F3istiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphoeytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
cell type
!~esentery
Lymphoma malignant mixed
0
5
E0
8
3
0
2
222
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF. FEMALE MICE : HIGH DOSE .
(Continued)
WEEKS ON
STUDY
.-
CARCASS
.
. .
.
ALIMENT
E
h
C&Md es r
Intestine large °
Intestine large, cecum
Lymphoma malsgnant lymphocytic
Lymphoma malignaat
Intestine large, colon
Intestine large, rectum
Intestine small
Intestine smail,duodenum
Lymphoma malignant Iymphocytic
Lymphoma malignant mixed
Intestine small, ileum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Intestine small,je7unum
Lymphoma malignant tymphocytic
Lymphoma malignant mixed
.
.
Liver
Hepatocellular carcinoma
Hepatocellularadeaoma
Hepatocellniaradenoma,multiple
Histiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma .malignant undifferentiated
cell type
Mesentery
Lymphoma malignant mixed
Pancreas
Lymphoma malignant lymphocytic
Salivary glands
,
Histiocytic sarcoma
Lymphoma malignant iymphocytic
Stomach
Stomach, forestomach
Stomach, glandular
Lymphoma malignant
Tooth
CARDTbViISL` ~J~$$$
Heart
Pericardium, lymphoma malignant
undifferentiated cell type
Adrenal gland
Adrenal gland, cortex
Lymphoma malignant
Lymphoma malignant undifferentiated
cell type
Adrenal gland, medulla
Islets, pancreatic
Parathyroid gland
Pituitary gland
Pars distalis, ado ooma
Pan intermedia, adenoma
Thyroid gland
Foilicularcell,adenoma
Follicular cell, carcinoma
0
5
(3
6
p
6
Q
6_
0
6,
0
6
0
6
0
6
0
6
0
6
4
6
0
6
0
6
0
6
0
6
0
6
0
6
0
6
0
8
0
0
6 ~6
0
6
0
6
0
6
0
6
7
3
6
_
6
2
6
3
7
2
8
1
8
2
0
2
1
3
1
4
3
4
4
4
6
2
6
3
7
1
9
1
9
2
1
1
1
2
3
1
3
2
3
3
4
1
9
2
4
3
.
M
-+
+
.
.
+
+
.
.
+
+
.
.
-F
+
.
.
+
+
.
.
+
+
.
.
+
+
.
.
+
+
.
.
+
+
.
.
+
+
.
.
tr
+
.
.
+
.
.
+
+
.
.
+
+
.
M
+
+
.
.
.
+
.
.
+
+
.
.
+
+
.
.
+
+
.
.
+
+
.
.
+
+
+
.
+
+
+
.
+
+
+
.
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
+
+
i-
+
+
+
+
+
+
+
t
-i+
+
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
F
+
+
+
+
+
+
i+
h
+
+
+
+
+
+
+
+
+
+
+
+
a+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4-
+
+
+
+
+
-F
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
x
+
+
+
+
+
+
+
+
+
g
+
+
+
+
+
i-
+
+
+
+
+
+
+
+
+
+
+
+
h
+
+
+
+
t
t
+
+
i-
+
+
+
+
.
+
+
t-
+
+
R
.
++
A
:(
.
X
X
+
+
%
X
%
.
i-
X
R
+
-h
+
+
+
+
+
+
¢
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
.
+
+
+
t
+
+
~
+
+
+
+
+
+
+
-1-f
+
+
+
t-
+
-p+
+
+
+
+
+
+
+
+
-f
.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
,t
+
+
. . .
+ +
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+ .
+
+
+
+
+
+
+
+
+
+
+
+
-h
+
+
+
+
+
+
+
+
+
t
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
i+
+
+
+
M
+
-8+
+
+
.
+
Prf.
+
X
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
X
+
+
+
+
+
t+
+
+
+
+
+
+
+
+
+
M
+
+
+
-r
-t
+
+
+
g
+
*
+
+
+
R
+
+
+
+
+
+
+
g
-
.
+
-F
+
+
.
+
.
+
+
+
+
+
+
-F
-F
+
+
+
+
+
+
-i+
+
-s-
+
+
+
+
+
+
+
+
-F
+
+
M
.
-~
-F
+
-1-
+
+
M
+
+
+
Y
+
+
+
+
-h
+
+
+
+
X
4+
+
+
k
+
+
+
+
X
t
+
+
+
%
+
i+
+
-+-
r
i-
+
+
g~
+
+
+
+
+
.
+
+
iiK
+
.
Tissue, NOS
223
Hydraquinone, IVTP TR 366
TABLE Y12 . INDIVIDUAL ANI MAL
WEEKS ON -
OR PATHOLOGY OF FEMALE MICE- HIGH DOSE
(Continued)
1
1
Y
11
5
I
5
2
6
1
7
L
7
2
"sophagus
Gallbladder
. .
Intestine large .
.
Intestine large, cecum
Lymphoma malignant lymphocytic
Lymphoma malignant
Intestine large, colon
Intestine large, rectum
.
Intestine small
Intestine small, duodenum
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Intestine small, ileum
Lymphoma malignant lympbocytic
Lymphoma malignant
jejunum mixed
Intestine small,
Lymphoma malignant lymphocytic
Lymphoma malignant mixed
Liver
Hepatocellular carcinoma
Hepatocellular adenoma
Hapatocellularadenoma,multiple
Histiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
cell type
+
+
+
+
.
+
+
+
+
+
+
'r
+
+
+
+
+
+
t
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
~
+
+
+
+
+
+
+
+
t
Pancreas
Lymphoma malignant lymphocytic
Salivary glands
HistiocyC:c sarcoma
Lymphoma malignant lymphocytic
Stomach
Stomach, forestomach
Stomach, glandular
Lymphoma malignant
Tooth
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-F
+
CARDIOVASCULAR SYSTEM
Heart
Pericardium, lymphoma malignant
undif7erentiated cell type
+
+
+
+
+
ENDOCRINE SYSTEM
Adrenal gland
Adrenal gland, cortex
+
+
+
-t
+
+
+
+
+
+
+
+
+
+
+
M
+
+
+
+
+
+
+
+
.
STUDY
CARCASS
ID
Mesentery
Lymphoma malignant mixed
Lymphoma malignant
Lymphoma malignant undifferentiated
cell type
Adrenal giand,medulla
Islets, pancreatic
Parathyroid gland
Pituitary gland
Pzrs distalis, adenoma
Pars intermedia, adenoma
Thyroid gland
FolIicuiar cell, adenoma
Follicular cell, carcinoma
.
a o 0 0 0
s s s s s
+
+
+
+
+
+
i-
+
+
+
TOTAL :
TISSUES
TUMORS
'
.
.
.
55
48
53
53
1
1
52
48
52
51
3
1
52
2
f
52
3
.
'
.
,
.
.
'
.
-
,
.
.
55
X
-
3
-
.3
X
+
+
+
i-
+
-I-
+
+
+
.
.
.
4
.
53
59
1
.
55
55
55
-
-
55
55
55
52
52
.
40
52
11
.
55
+
.
.
GENERAL BODY SYSTEM
Tissue, NOS
Hydroquynone, NTP TIZ 366
11
1
1
224
.
-
99E 2I,I. dLRI `auoczonboaPfiH
]u
'1'
+
+
-1-
i-
I-
$
+
-F
-h
i'
+
+
+
+
.
.
+
+
-7-
+
+
+
+
4
+
+
g
+
+
+
9ZZ
+
+
.
.
+
+
+
.
,
'f
+
1-
t
+
+
f
+
-{'
+
.
+
d-
+
$
+
$
+
-F
+
k
+
-F
+
i-
+
.
4
'F
+
i-
+
.
t
'F
+
-F
+
.
+
'I-
.
'{-
+
,
.
i-
-h
][
YS
-F
-i-
y
X
X
t
-F
t
t
+
-F
x
x
+
+
+
+
+
+
+
X
-F
~
+
}(
-f
.
'F
X
%
..
W
..
NY
.
.
.
~
$
+
t
](
'F
$
.
7f
i-
x
X
-F
i-
+
+
+
-F
x
}[
V
-F'
i'
Ytl
NT
$
x
$
i-
\ $
'1-
-F
](
+
~
-F
h
NJ
-F
.
+
'F
.
-F
t
-F
t
t
+
t
.
3uev8iism emoqdm6Z
ai~snm te3e~a~g
anog
WBt.SiS TdT.~'t'~u407R~Sf1W
IIn[g
.
..
.
pBIE1juB307~IpIIII'~IIE12$SIEt712LIIOS[~UII1A']
B
p8%ISIIjIIEIIBl(BIIIEIIIOlltIWICq
jQEUPTj2Sll EWOljlISII/~a"j
ol'OS;(IIIItSt'{IIETISIiuLSTIIOllfIWF.l
3i'{AJDI'}Stl('jII$TI8lj8UlEIIIOI[(IlIIlt'I
.
.
.
SRiIIISiW.
edeC~y Iia~
peazcque.ca,~cpan ZueuSctam ecaoqdm6Z
pexcm auev2ijem etaoqdmAZ
auenbitem emor[dm67
X .
.
.fm smoij
3la~.7Raoam~T'
.9s .q9ae8ijul
.dm6'I
tII oBjd~y
-F
peast ;nose,utpanluenBelewe oqdm 6Z
pemm guea8iisw emoqdm6l
x
as3oua~ .ct ~aQEaltIEW
+
+
+
W,
+
N
+
+
f
'f-
N]
-F
~-
z
a~eluesam 'a
penm jvea8item emoqdm6l
Iuevsiisac emoqam6,]
3SjAJOS[dUIF,t jIIEIIHlIEi73 EL~Ol;fIIISA'I
.
.
~
EUEO fISIlaS7
JL'J~~OI~S7T(jIIES7SlIEt17 ESIIOlt(ISII1L7
Bi120J.3CS DqAO0pStH
.
+
x
.
JY'{I~aOfISSi{ ;ven8ilem swoqdmgj
~
EIIP0oIES Jl'{7(oOI;SlH
-{'
axiw 3veuHteml¢
mod
~~
l
ii ~II
1 ~Feue 2I
jveu8itam emoqdm6l'tesaridoa
.
.Y
emo~issot8uemaq
'ansstq snoene4n3qns bi3esoqy
scuoqdm6~ "anssc; sno aueactia9nS
f
smoucaiz :)onepy
puel8 lsscumeyq
yd:a i.eAc XiiV T mSLYR a t m2
Ird
.
](
-I-
%
-F
7C
~
+
e 6i~
d
y'e~~~
pelecavaia~ytpvn'~QEIIHtiEiYi Hi730S[aQItC'I
.
+
g
X
pextut i¢eu8ilam svtoqdm6jbpeesauea
jvev8ijem ezuoqdm6j'ai3ae.=aveT
3tj601{diIIfCl
aII24EljE9] EE[OL[dLiiSj'JIqE8So48d
X
x
.
3ia.t3oiIs,q
,
jueuSitem enzoqdm6~ `aI~EBd~92a
E[IIOo.lE3 JSq(oOl'jSq'aIp82*9Ea
;II2ll8lIBill 2YQOL1di11At'jEIITaSEIpBw
aI{X70[I(ISIICl
][
aIIBII81tEII7 EII7DLi(1SI]67` 'ievt;setpey,~
%
pax4m aIIEIIHl(Eia $i7ZO1;aW7Sl'1Ef;WR']
%
%
3c°RaoqdtuFla
~¢eu8i[~em zcuo~I
~ du~61t `i¢9
" qmn7
~
a
Oq{]OIjS?i; a V EIIHS(EL71 EIIIOitdAllCl 'saqtanl
jIIEURltESII E7IIDq(III7Al'iE9IRHIIi
.
.
X
%
~'
ntjkaoqdmRl
3IIHIIHltEII7'¢1II04(fISIIA' 'tEi]TIlBIIl
paxcm 3nen8c1em smo~dcn6j °osclI
laen8qem emoqdm6i "osilI
9uen8zteai emoqdmdf `fiEl1~V
X
X
X
-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-F
+
+
+
+
+
+
+
+
V
+
+
+
+
+ +
x,
+
+
+
+
+
+
+
+
+
+
+
+
X
+
+
+
+
+
+
+
+
+
+
+
+
yq
+
+
+
+
+
+
+
+
+
+
mauam euoH
lS3,T,4AS pI .SIOdO iynsH
+
+ V+
JSa/C3Olj(Y271St
yvev8ctem sruoqdwfil 'tiE11?xd
ai~oi3stq
3nsv8t.tem ¢moqdm SI 'tiEli?%V
7uev8itexn smoildm6q
epon qdm6Z
g
+
+
S
Y
L
T
Z
L
+
Snjaan
aax3
yIa3 paqeYave.ia~pun gnev~ijem
Ewoqdmd~ 'anssia vsvanovaa
.
$
X
X
peaim gveuFitem
aeuoqdm6l 'enss}a pevenouad
aueu8iiew eutoqdm.Sj 'anssiy nevenouaa
.
.
ocyCooqdm6l3ven8ijem
emox[dmAl'snsst3 vevenovaa
$
r
f
+
£
6
9
+
S
8
9
+
!~
8
9
E
8
9
+
+
T
B
L
5
6
9
T
T
i
T
T
I
goaxem ;98SiHIjEll7 EIIIDI[aill~'j
.
+
Z
8
L
'9I
t
b
9
9
3
L
-L
+
E
9
G
+
,-
9
9
L
.
+.
4 9
9
L
L . 9
E
B
L
3 9 9 9 9 9 s 9 i 0 s 9 v v 9
0 0 0 0 0 0 0 0 0 0 6 9 6 6 6
_ I- T
T
T
0
0
0
0
+
4
L
9
+
+
9
9
9
+
9
0
L
9
8
P.
+
T
0
P.
f
-t-
v
9
L
9
Z
L
-F
-
0
0
0
0
0
0
0
0
2nen8ilem smoqdmX7
emovepe3s6D
t
Z
9
L
flenp
paetH tesoIt10
rn~~ssas ~rvs,iu~~
9 .
Z
L _
0
-
QI
SSV~'tI`J~
z e a 6 9 0 ^ e e z
6 9 9 L 9 7
0 0 0
0
0
xanss
1d
SSIil3M
(paIlBIp¢Ioa)
aSOa Hf)II-i :aC)TN H'2VLOIH3 30 XDO"IOHJ,Vd 2id)FhttlL 'IV3AIINV 'IVf1CtI11IUISI 'ZQ H'IUV9..
TABLE D2.
INDIVIDUAL ANIMAL, TuMOR
WEEKS UN
STUDY
CARCASS
ID
GENITAL
Clitoral gland
Ovary
Cystadenoma
PATHOLOGY OF FEMALE MICE : HIGH DOSE
(Continued)
1
0
5
1
0
6
1
0
6
1
0
8
1
0
6
1
0
6
1
0
6
2
0
6
I
0
6
1
0
6
I
0
6
1
0
6
1
0
6
L
0
6
1
0
6
1
0
.6
1
0
6
L
0
6
1
0
6
1 - 1 1
1
1
1
0
0
0
0
0
0
6
6
6
6
6
6
7
3
6
1
6
2
6
3
7
2
8
1
8
2
0
2
2
3
1
4
3
4
4
4
6
2
6
3
7
2
9
1
9
2
1
1
1
2
3
1
3
2
3
3
4
1
4
2
4
3
+
+
+
+
.
+,
+
+
.
+
i-
-q-
-F
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ ~ +
-3-
-h
+
+
+
+
+
+
+
i-
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
-a
+
f
+
+
+
+
+
+
+
+
+
_p.
Lymphoma malignant
Lymphoma malignant mixed
Periovarian tissue, lymphoma
malignant
Periovarian
Periovarian
malignant
Periovarian
malignant
type
lymphocytic
tissue, lymphoma malignant
tissue, lymphoma
mixed
tissue, lymphoma
undifferentiated cell
Uterus
Bone marrow
Lymph node
Lymphoma malignant
Axillazy, lymphoma malignant
hisCiocytic
.
Axillary, lymphoma malignant
lymphocytic
Axillary, lymphoma malignant
Iher, lymphoma malignant
Iliac, lymphoma malignant mixed
Inguinal, lymphoma malignant
lymphocytic
Inguinal, lymphoma malignant
Lumbar, lymphoma malignant histiocytic
Lumbar, lymphoma malignant Iymphocytic
Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
Mediastinal, lymphoma malignant
lymphocytic
Pdediastinai, lymphoma malignant
Pancreatic, histiocytic sarcoma
Pancreatic, lymphoma malignant
bistiocytfc
Pancreatic, lymphoma malignant
lymphocytic
Pancreatic, lymphoma malignant
Pancreatic, lymphoma malignant mixed
Popliteal, lymphoma malignant
Renal, lymphoma malignant mixed
Lymph node, mandibular
Histiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifFerentiated
ce11 type
Lymph node, mesenteric
Histiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
cell type
Spleen
Lymphoma malignant histiocytic
Lymphoma
Lymphoma
Lymphoma
Lymphoma
cell type
Thymus
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
cell type
,
_
+
+
+
+
+
.
+
I
Mammary gland
.
Adenocarcinoma
Skin
Subcutaneous tissue, lymphoma
malignant
Thoracic,subcutaneous tissue,
hemangiosarcoma
Bone
Skeletal muscle
+
+
+
.
-i-
-#-
-
+
+
t-
+
+
+
+
+
+.
+
.
.
.
g
.
.
_
+
t
+
+
+
+
+
+
+
+
+
+
+
M
+
M
+
+
+
+
+
+
+
X
g
+
+
g
g
+
+
g
X
+
+
+
,-
+
+
+
+
+
+
+
+
+
+
.
+
+
+
-I-
+
+
¢
+ . + . +
+
+
+
-3-
+
+
+
+
+
+
+
+
+
X
X
%
+
+
h
X
+
+
+
+
+
+
+
x
+
+
+
+
M
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
g
-
+
+
+
+
U2
.
+
+
+
+
+
+
+
+ - +
+
+
+
i-
+
+
+
+
+
+
+
-F
+
-!-
+
i-
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
Lymphoma malignant
k-Iydroquinone, NTP TR 366
+
-
malignant lymphocytlc
malignant
malignant mixed
malignant undifferentiated
malignant histiocytic
malignant Iymphocytic
malignant
malignant mixed
malignant undifferentiated
.
226
.
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: HIGH DOSE
(Continued)
a a o o a
CARCASS
ID
GENITAL SYSTEM
Clitoral gland
Ovary
CysYadenoma
Lymphoma malignant
Lymphoma malignant mixed
Periovarian tissue, lymphoma
..
malignant lymphocytic
Periovarian tissue, lymphoma
tissue, lymphoma malignPerov
malignant mixed
Peciovaria¢ tissue, lymphoma
malignant undifferentiated cell
type
6
6
6
5
1
5
2
6
1
+
+
+
_
6
7
1
7
2
+
TOTAL-
1
54
1
L
1
+
3
1
1
Uterus
+
+
+
n MATOPOIETIC SYSTEM
Bone marrow
-I-
i-
t
Lymph node
Lymphoma malignant
Asillary, lymphoma malignant
histiocyt%c
Amllary, lymphoma malignant
lymphocytic
l4xitlary, lymphoma malignant
Iliac, lymphoma malignant
6
+
+
t
I
,
+
SS
F
-F
54
54
t
~-
1
1
1
L
1
Inguinal, lymphoma malignant
Lumbar, lymphoma malig. histiocytic
Lumbar, lymphoma malig. lymphocytic
. Lumbar, lymphoma malignant
Lumbar, lymphoma malignant mixed
MediastinaI, lymphoma malignant
2
lymphocytic
ikYediastinal, lymphoma malignant
Pancreatic, histiocytic sarcoma
Pancreatic, lymphoma malignant
histiocytic
Pancreatic, lymphoma malignant
.
2
1
1
1
Lymph node, mandibular
Histiocytic sarcoma
+
+
+
+
.
3
1
1
1
1
49
1
1
6
2
2
Lymph node; mesenteric
ETistiocytic sarcoma
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic,
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
cel type
+
+
+
+
+
52
t
lymphocytic
Pan,creatic, lymphoma malignant
Pancreatic, lymphoma malignant mixed
Popliteai, lymphoma malignant
Renai,lymphoma malignant mixed
-
I
1
3
2
I
Iliac, lymphoma malignant mixed
Inguinal, lymphoma malignant
lympbocytic
.
i
1
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
call type
Spleen
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
cell type
malignant histiocytic
malignant lymphocytic
malignant
malignant mixed
malignant undifferentiated
Thymus
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
cell type
malignant histiocytic
malignant lymphocytic
malignant
malignant mixed
malignant undifferentiated
malignant histiocytic
malignant lymphocytic
malignant
malignant mixed
malignant undifferentiated
Mammary gland
Adenocarcinoma
Skin
Subcutaneous tissue, lymphoma
malignant
Thoracic, subcutaneous tissue,
- hemangiosarcoma
MUSCULOS
Hone
Skeletal muscle
Lymphoma malignant
EItK
1
1
7
3
5
X
' +
+
+
+
+
+
i-
1
55
1
7
3
4
R
i-
+
i-
1
47
L
4
1
1
1
+
+
+
i-
+
+
t-
t
i°
t
53
2
55
I
1
+
+
+
+
55
1
1
227
Hydroquinone, N'I°F'TR, 366
TABLE Y)2 . INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: HIGH DOSE
(Continued)
wE~K ON
STUDY
CARCASS
ID
NERVOUS SYSTEM
Brain
Lymphoma malignant mixed
Spinal cord
.
0 0 0 0 0 0 0
0
1
0
8
0
3
0
8
2
0
5
6
7
8
0 0 0 0 0
8
1
8
9
9
2
9
2
9
4
0 0 0 1 1
9
4
9
6
9
8
2
5
2
2
2
3
2
4
0
1
8
5
0
3
6
5
7
4
8
3
7
3
6
4
3
5
5
3
7
4
+
+
+
+
+
,'-
+
+
+
+
+
+
+
t-
L
g
Aaeolarlbmnchiolar adenoma
Alveolazlbronchiolar adenoma, multiple
Alveolar/bronchiolar carcinoma
Carcinoma, metastatic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
' cell type ,
t
+
+
+
+
+
-t-
+
+
+
+
+
+
-r
+
Eye
Harderian gland
Adenoma
Carcinoma
Lacrimal gland
Hydroquirione, NTP TR 366
+
+
+
+
+
,
+
+
+
+
+
++
+
+
-h
0
1
0
3
1
1
1
1 1
0
5
0
5
0
5
0
5
0
5
6
4
7
8
2
6
9
4
7
8
1
6
8
3
6
8
4
6
8
5
6
9
3
7
1
5
2
1
+
+
+
+
+
.
.
+
+
+
+
+
+
+
+
+
+
¢
+
F
i
+
+
+
X
+
-S-
0
5
0
5
+
R
Trachea
Nose
MUMMY SYSTEM
Kidney
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Capsule, lymphoma malignant
lymphocytic
Renal tubule, adenoma
Urinary bladder
Lymphoma malignant
+
+
+
0
0
t
+
+
-F
+
+
+
+
g
+
.
+
+
t
P,
.
+
+
+
+
.
1
1 1-
%
.
t
+
+
+
+
+
+
+
+
+
+
+
+
+
+
.
+
+
+
+
+
+
+
i-
+
+
+
+
+
+
+
+
X
-F
+
+
+
+
+
+
+
.
+
.
+
X
X
R
g
X
-F
.
+
i-
+
+
-i-
228
-a-
+
+
.
+
+
+
+
+
+
g
+
A
t
+
+
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE : HIGH DOSE
(Continued)
WEEK
STUDY V
h
0
5
CARC3SS
ID
Brain
OUS SYSTEM
Lymphoma malignant mixed
.
Spinal cord
x
i
.
Luag
Alveolarfbronchiolar adenoma
Alveolarlhronchiolar adenoma, multiple
Alveolar/bronchiolar carcinoma
Carcinoma, metastatic
'
Lymphoma malignant lympbocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
cell type
Nose
Trachea
i
0
6
1
0
6
-7~'s
7
6
1
3
6
2.
.
+
.
.
.
-!-
1
0
6
6
3
+
+
+
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Capsule, lymphoma malignant
lymphocytic
Renal tubule, adenoma
Urinary bladder
Lymphoma malignant
+
+
.
1
1
3
+
-h
+
t
+
0
6
1
4
.
1
1
0
6
0
2
.
+
1
0
6
0
6
8
2
3
4
i-
1
0
6
4
4
+
1
0
.6
+
.
1
0
8
0
6
i-
+
+
1
0
6
1
1
1
1
7
1
2
3
1
3
2
+
+
+
+
0
6
0
8
6
2
6
3
7
1
9
1
6
9
2
+
.
.-
+
+
. .
+
1
1
.
+
+
1
0
6
0
6
1
0
6
1
0'
6
1 -1 0 0
6
6
3
3
4
1
4
4
+
+
0
6
.
+
+
+
+
+
2
.
+
t
+
3
+
.
+
+
'
+
+
+
,+
+
+
+
+
+
+
+
~b
+
+
+
+
+
+_ +
+
+
+
+
+
+
+
T
.
+
+
+
.
+
.p.
-t
i-
i-
+
R
R
h
+
-
-
..
+
+
+
.
+
X
R
Eye
Harderian gland
Adenoma
Carcinoma
Lacrimal gland
Kidney
1
0
6
8
1
+
.
1
0
8
7
2
.
+
1
0
6
+
229
i-
+
+
+
+
+
+
.
+
+
+
+
+
+
+
+
+
+
+
+
+
t
+
+
+
+
+
+
+
+
+
+ , +
+
+
r
+
+
+
+
+
..
+
+
t
+
-
+
+
+
+
+
R
X
.
.
+
+
+
X
X
+
+
+
.
+
+
+
+
+
+
X
_
+
+
+
+
Hydroquinone, N'rP TR 366
TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE
MICE : HIGH DOSE
(Continued)
WEEKS ON
. STUDY
-
CARCASS
ID
1
0
6
1
0
6
1
0
6
-T- 'r--q-5
5
6
7
1
2
2
1
7
2
Brain
Lymphoma malignant mixed
Spinal cord
HE
Lung
A2veolar/bronchiotar adenoma
Alveolar/bronchiolar adenoma, multiple
Alveolar/bronchiolar carcinoma
Carcinoma, metastatic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Lymphoma malignant undifferentiated
cell type
Nose
Trachea
1
0
6
1
0
6
+
+
-~
X
+
+
+
+
-}
i-
+
55
Z
3
55
1
%
I
2
1
P
3
2
X
+
+
+
+
+
+
+
+
+
+
Eye
Harderian gland
Adenoma
Carcinoma
Lacrimal gland
RINAR
Kidae
Lymphoma malignant histiocytic
Lymphoma malignant lymphocytic
Lymphoma malignant
Lymphoma malignant mixed
Capsule, lymphoma malignant
1ymphocytic
Renal tubule, adenoma
Urinary bladder
Lymphoma malignant
TOTAL:
TISSUES
TIUMOR§
55
ss
5
7
+
+
+
+
2
+
-
;;
+
+
+
+
55
1
4
3
3
1
+
54
I
i
I-iydx°oquinone, NTP TR 366
230
TABLE I)3 : ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR GAVAGE STUDY
OF HYiDROQUFNONE
Vehicle Control
50 mg/kg
100 mg/kg
Harderian Gland: Adenoma or Carcinoma
Overall Rates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Tests (d)
Logistic Regression Tests (d)
Cochran-Armitage Trend Test (d)
Fisher Exact Test (d)
2/55(4%)
52%
1/37(3%)
693
P=0 .249
P=0 .245
P=d .2b3
2/55(4%)
5 .1%
2/39(5%)
735
P=0 .672I`T
I'=0 .6641V
4/55(7%)
10 .3%
3136(8%)
641
P=fl .338
P=0 .331
P=0 .691N
F'=0 .339
Liver : gIepatocetitiiaa° Adenoma
Overall Rates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Tests (d)
Logistic Regression Tests (d)
Cochran-Armitage Trend Test (d)
Fisher Exact Test (d)
2155(4%)
5 .4% . .
2l3'1(5%)
735
I'=0 .d07
P=0 .007
P=0 .009
15/55(27%)
36 .2g°o
13/39(33%)
534
P---0 .001
P=o.aar
12/55 (22%)
30 .39'a
9/36(25%)
656
P=0 .005
P=0 .d05
P<0 .001
P=0 .004
Liver: HepatocetIular Adenoma or Carcinoma
Overall Rates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Tests (d)
Logistic Regression Tests (d)
Cochran-Armitage Trend Test (d)
Fisher Exact Test (d)
3/55(5%)
8 .1%
3/37 (8%)
735
P=0 .009
P=Q .009
F'=b .011
16/55(29%)
37 .6%
13/39(33%)
534
P=0 .002
P=0 .002
13/55(24%)
32 .9%
10/36(28%)
656
P=0 .007
P=0 .007
P<0 .001
P=0 .006
Lung: Alveolar/Bronchiolar Adenoma
Overall Rates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Tests (cl)
Logistic Regression Tests (d)
Cochran-Aemitage'Frend Test (d)
Fisher Exact Test (d)
3/55(5%)
7 .1%
1/37(3%)
558
P=0_434N
P=0 .436N
F'=0 .424N
6/55(11%)
14 .4%
4/39(10%)
660
P=0 .283
P=0256
2/55(4%)
5 .6g'o
2/36(6%)
735
P =0 .507N
P=0 .510N
F'=0 .244
ff'=0 .500N
6155(11%)
14.4%
4139(10%)
660
P=0 .41d
F=0 .393
4/55(7%)
21 .13'a
4/36(11%)
735
P=0 .63P
P=0 .633
P=(} .371
P=0.642IV
5/55(9%)
12 .8'Yo
5/39 (13%).
735
P=0 .384
P=t3 .355
2/55(4%)
5 .0%
1/36 (3%)
&56
P=U .512N
P=0 .491N
P=d .358
P=0 .500N
Lung :. Alveolar/Bronchiolar Adenoma car Carcinoma
4/55 (7%)
Overall Rates (a)
9.630
Adjusted Rates (b)
2137(5%)
Terminal Rates (c)
658
Day of First Observation
P=0 .556
Life Table Tests (d)
P=0 .560
Logistic Regression Tests (d)
P=0 .56$
Cochran-Armitage Trend Test (d)
Fisher Exact Test (d)
Mammary Gland: Ade%HOCRrCi92o8Y1a,
Overall itates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Tests (d)
Logistic Regression Tests (d)
Cochran-Armitage Trend Test (d)
Fisher Exact Test (d)
3/55(5%)
72%
2/37(5%) .
372
P=0 .434N
P=0 .4301V
P =0 .421 Pd
231
-
Hydraquinone, NTP TR 366
Vehicle Control
Pituitary C:tancl/Pars Distalis: Adenoma
Overall Rates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Test (d)
Logistic Regression "Pest (d)
Fisher Exact Test (d)
11/52(21%)
30 .0'Yo
9/34(26%)
664
Pituitary GflatadIl'ars I)istalis : Adenoma or Carcinoma
Overall Rates (a)
12/52(23%)
Adjusted Rates (b)
31 .5%
Terminal Rates (c)
9/34(26%)
Day of First Observation
631
Life Table Test (d)
Logistic Regression Test (d)
Fisher Exact Test (d)
Thyroid Gland : Follicular Cell Adenoma
Overall Rates (a)
Adjusted Rates (b)
Terminal Rates (c)
Day of First Observation
Life Table Tests (d)
Logistic Regression Tests (d)
Cochran-Armitage Trend Test (d)
Fisher Exact Test (d)
50 mg/kg
100 mg/kg/
(e) 14129 (4.8%)
11/52(21%)
29.896
8/33(24%)
644
P=0 .575
P=p,5g5N
P=0 .595N
(e) 16/29 (55%)
11/52(21%)
23 .8%
8/33(24%)
644
P=0.518N
P=0.497IV
P= 0.500N
3/55 (5%)
? .7%
2/37(5%)
664
P=0 .190
P=0 .188
P=0 .fl9&
5/55(9%)
12 .2%
4/39(10%)
668
P=0.394
I'=0.397
6/5501%)
I5 .39'0
4/36(11%)
548
P=0240
P=0 .233
P=0 .3S3
P =0244
Thyroid Gland: Follicular Cell Adenoma or Carcinoma
Overall Rates (s)
3/55(5%)
Adjusted Rates (b)
7 .7%
Terminal Rates (c)
2/37 (5%)
Day of First Observation
664
Life Table Tests (d)
P=0 .11$
Logistic Regression Tests (d)
P=0 .I15
Cochran-Armitage Trend Test (d)
P=0 .123
Fisher Exact Test (d)
5/55(9%)
12 .2%
4/3900%)
668
P=0 .394
P=0 .397
7/55(13%)
17.9%
5136 (14%)
S4$
P=0 .157
P=0 .152
P=0.3S8
P=0 .160
Hematopoietac System : Lymphoma, All Malignant
Overall Rates (a)
23/65(42%)
Adjusted Rates (b)
52 .8%
Terminal Rates (c)
17/37(46%)
Day of First Observation
463
Life Table Tests (d)
F'=0 .266N
Logistic Regression Tests (d)
P=0263N
Cochran-Armitage Trend Test (d)
P=0238N
Fisher Exact Test (d)
12/55(22%)
25.4%
6/39(15%)
409
P=0 .Q181V'
P=0 .0211dT
19/56 (35%)
41 .2%
9/36(25%)
622
P=0 .309N
P=0 .313N
_P=0 .020Iet
P=0 .278N
(a) Number oftumar-bearing animals/number ofanimals examined at the site
(b) Kaplan-Meier estimated tumor incidences at the end ofthe study after adjusting for intercurrent mortality
(c) Observed tumor incidence at terminal kill
(d) Beneath the vehicle control incidence are the P values associated with the trend test . Beneath the dosed group incidence are
the P values corresponding to pairwise comparisons between that dosed group and the vehicle controls. The life table analysis
regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death . The logistic regression test regards these lesions as nonfatal . The Cochran-Armitage and Fisher exact tests compare directly the overall incidence
rates. A negative trend or lower incidence in a dosed group is indicated by (N) .
(e) Incomplete sampling oftissues
Hydroquincsrae, NTF' TR 366
232
TABLE ID4a. HISTORICAL INCIDENCE ()F" HEP'ATOCEY.L,ULAIt TUMORS IN FEMALE B6C3Fj MICE (a)
Study
Adenoma
Incidence in Controls
Carcinoma
Adenoma or
Carcinoma
Historical Incidence for A91 Water Gavage Vehicle Controls
Iodinated glycerol (b)
ChIorpheniraraiine maleate (c)
Tetrakis(hydrorymethyl)phosphonium chloride (c)
ASalonaIdehyde, sodium salt (c)
Tetrakis(hydrogyfnethyl)phosphonium sulfate (C)
Methyl carhaanate (rl)
Chlorinated trisodiexm phosphate (b)
TOTAL
SD (e)
0/50
4l50
3149
0/50
5/"s0
4/49
6150
0/50
2/50
1/49
2150
3150
Y049
4/50
22/348(6 .3%)
4 .699'0
Range (f)
High
Low
Ol50
6/50
4/49
2A50
7/50
4149
60b0
91348 (2 .6'~'0)
222% °
6/50
0/50
3/50
0I50
1Q7/2,032 (5 .3~'0)
4 .34%
(g) 83/2,032 (4 .03'a)
2 .42%
9/49
0150
4/48
0/50
291348 (8 .39b)
4 .95%
7/50
0/50
Overall Historical Incidence for Untreated Controls
TOTAL
SD (e)
Range (f)
High
Low ,
v->
(g) 184/2,032 (9 .1%)
4 .70%
10149
1150
(a) Data as of April 29, 1987, for studies of at least 104 weeks
(b) Study performed at EG&G Mason Research Institute
(e) Study performed at Battel2e Columbus Laboratories
(d) Study performed at Microbiological Associates
(e) Standard deviation
(f) Range and SD are presented for groups of 35 or more animals.
(g) One hepaLoblastoana was also observed .
233
Hydroqezinone, NTP TIZ 366
TABLE D4b . HISTORICAL INCIDENCE OF THYROID GLAND FOLLICULAR CELL TUMORS IN FEMALE
B6C3F'Y MICE (a)
Adenoma
Incidence in Controls
Carcinoma
Study
Adenoma or
Carcinoma
Historical Incidence for A11 Water Gavage Ve hicle Controls
Iodinated glycerol (b)
Chtorpheniaamine maleate (c)
Tetrakis(hydragymethyl)phosphoniuan chloride (c)
2dladomaldehyde,.soditena salt (c)
TeCrakis(hydroxymethyl)phosphonium sulfate (c)
Methyl carbaanate (d)
Chlorinated trisodium phosphate (b)
TOTAL
SD (e)
2148
a148
1148
3148
1/49
8148
1/48
10/337 (3 .0~3'0)
2 .04%
Range M
High
Low
3/48
0J48
Overall Historical Incidence for Untreated Co ntrols
TOTAL
SD (e)
Range (f)
High
Low
01337 (0.03'0)
0 .00'Yo
0/49
0149
2148
0/48
1/48
3/48
1/49
2/48
1/48
100337 (3 .0%)
2 :04°10
3A48
0/48
.
.
(g) 411Y,937 (2 .1 %)
2 .58%
4/48
0f50
(a) Data as of April 29,1987, for studies of at least 104 weeks
(b) Study performed at EG&G Mason Research Institute
(c) Study performed at Battelle Columbus Laboratories
(d) Study performed at Microbiological Associates
(e) Standard deviation
(fl Range and SD are presented for groups a4 35 or more animals .
(g) Includes two cystadenomas, IVOS, and one papillary cys2adenoma, NOS
Hydroquincrney N'I'P TR 366
0148
0/48
0/48
fli4$
0149
0148
O/4A
234
SI1,937 (0 .4~'0)
1 .17%
3/48
0/50
(g) 4911,937 (2 .5%)
3 .22%a
7l48
0050
TABLE Il5o SUMMARY OF THE INCIDENCE OF NONNEOPI.AS°TIC LESIONS IN FEMALE MICE IN THE
TWO-YEAR GAVAGE STUDY OF HYDROQUINONE
Vehicle Control
Animals initially in study
Animals removed
Animals examined histopathologically
ALIMENTARY SYSTEM
Gallbladder
Inflammation, chronic
Mucosa,hyperpiasia,focal
Intestine large, cecuan
Colon, serosa, inflammation, chronic
Intestine small, duodenum
Muscularis, inflammation, acute
Sesosa, ileum, jejunum, inflammation, chronic
Intestine small, ileum
Amyloid deposition
Intestine small, jejunuan
Pe3rer's patch, hyperplasia, lymphoid
Liver
Amyloid deposition
Angiectasis
Basophilic focus
Congestion
Cyst
Eosinophilic focus
Fatty change
Focal cellular change
Hematopoietic cell proliferation
I-Yqperplasia, lymphoid
Inflammation, chronic
Inflammation, granulomatous, focal
Mixed cell focus
Necrosis
Biliary tract, inflammation, chronic
IGupffer cell, hyperplasia
Mesentery
Inflammation, chronic
Inflammation, suppuratave
Necrosis, focal
Fat, hemorrhage, focal
.
Fat, necrosis, focal
Fat, lymphatic, hemorrhage, focal
Perivascular, inflammation, chronic
Pancreas
Inflammation, chronic
Inflammation, subacute
Duct, ectasia
Salivary glands ,
Inflammation, chronic
Stomach, glandular
Erosion, focal
Low Dose
High Dose
65
65
5s
65
65
55
(50)
1 (2%)
(12)
(48)
(52)
(13)
1 (2%)
(53)
65
65
55
(52)
(49)
1 (2%)
(52)
1 (2%)
(56)
1 (2%)
2 (4%)
I (2%)
3 (5%)
4 (?%)
3 (5%)
5
2
1
3
f
1
(19)
2
1
(9S'o)
(2%)
(29'o)
(5%)
(29`a)
(2°Ia)
1
11
1
1
(54)
7
I
1
(54)
25
(53)
(59'a)
(589'a)
(5°l0)
(5%)
(I1%)
(5%)
(2°k)
(23°0)
(23'0)
(469'0)
235
(89°0)
(15)
1 {7~03
i (79'0)
(14)
(51)
(52)
I (2%)
(52)
(12)
(55)
2 (4o)
fr (1E9'o)
1 (2t%)
3 d59'o>
2 (4%)
(55)
1 (2%)
3 (5%a)
1 (2%)
2 (4%)
1 (2%)
1 (2%)
1 (2%)
1 (2%)
4 (79'0)
b (99b)
2 (4%)
2 (4°k)
(12)
i (89'0)
1 {8'Yo)
2 (89°o)
(4)
6 (60%)
2 (509'0)
f1SD
3 (199°0)
(53)
1 (29'0)
1 (6%)
(54)
34 (fi3%)
(16)
1 (6901
(54)
33 (61%)
(55)
Hydroquinone, NTP 'I°R 366
TABLE gB5. SUMMARY OF THE INCIDENCE OF Nt)NNEOPI,AS"d'IC LESIONS IN FEMALE MICE IN '1'I-¬E
TWO-YEAR GAi7_t1C,'rE STUDY OF HYDROQUINONE (Continued)
Vehicle Control
CARDIOVASCULAR SYSTEM
Heart
Cardiomyopathy .
Hemorrhage
Inflammation, chronic
. Atrioeentricular valve, inflammation, subacute
` Atrium, thrombus
'
Coronary artery, inflammation, chronic
Epicardaum, inflammation, chronic
ENDOCRINE SYSTEM Adrenal gland, cortex
Degeneration, diffuse
Degeneration, focal
I-Iematopoietic cell proliferation
Iiyperplasia, focal
Adrenal gland, medulla
giyperplasia,focal .
Pituitary gland
Paes distalis, angiectasis
Pass distalis, hyperplasia, focal
Thyroid gland
Inflammation, chronic
F'olyarteritis
Follicle, cyst
Follicular cell, hyperplasia
(55)
1 (2%)
1 (2%)
1 (23°0)
1 (25'0)
1 (2%)
(55)
Low Dose
(17)
(55)
1 (6°l0)
I (6%)
1 (6%)
(13)
(59'0)
(2%)
(2%)
(253'0)
(5%)
13 (2496)
1 (2%)
fl (29'0)
(55) .
1 .(2%)
2 (43°0)
3
(61)
?
(52)
E
13
(55)
3
High Dose
4 ( 7%)
2 (4%)
(52)
(11)
(29)
2
4
(55)
4
1
(7%)
(14°l0)
(7%)
(2%)
47 (85~'0)
.
(52)
4 ($9'0)
13 (25%)
(55)
9 (169'a)
1 (2%)
45 (S2%)
GENERAL BODY SYSTEM
None
GENITAL SYSTEM
Ovary
Angiectasis
Cyst
Fibrosis
Hemorrhage
Inflammation, chronic
Inflammation, sesppurative
Necrosis
~
Thrombus
Artery, periavarian tissue, inflammation,
chronic
Periovarian tissue, inflammations chronic
Perimvarian tissue, inflammation, subacute
Perrovarian tissue, necrosis
Serosa, hyperplasia, papillary
Uterus
Iiydrometra
Inflammation, chronic
Endoenetrium, hemorrhage
Ezadometrium, hyperplasia, cystic
Endometrium, inflammation, suppurative
Myornetrium, hyperplasas
Submucosa, angiectasis
Hydroqaunone,NTP TR 366
(55)
12 (223'0)
1 (2%)
1 (2%)
(S3)
1 (Z%)
12 (23%)
f54)
14 (26~°0)
1 (2%)
1 (2%)
1 (2%)
1 (29b)
5 (996)
1 (2°l0)
(54}
2 (49'0)
1 (B3'o)
37 (&9%)
2 (4%)
1 (2`,6)
5 (9`9o)
1 (2%)
(29)
2 (33'0)
1$ (62%)
4 (7°Jo)
1 (29'0)
(55)
2 (4%)
31 (563'0)
1 (2%)
i (29'o)
236
_._~
TABLE I.)5. SUMMARY OF THE INCIDENCE OF PdONNE0PY .AS'IIC LESIONS IN FEMALE 1SUCE IN THE
TWO-YEAR GAVf1GE STUDY OF FI°YDfft(3QUIN0NE (Continued)
Vehicle Control
i
'
!
l
i
'
;
I
!
i
;
;
'
il
,
'
i
i
i
i
,
I
'
'
HEMATOPOIETIC SYSTEM
Bone
ow
Hyperplasia
Lymph node
HYlerplasia, plasma cell
tL$iBlaxy, hyperpla§ia, lymphoid
Axailary, hyperplasia, plasma cell
Deep cervical, hyperplasia, plasma cell
Iliac, hematogoietic cell proliferation
Inguinal, hematopoietic cell proliferation
Meciiastinal, hematopoietic cell proliferation
Mediastinai; hyperplasia, lymphoid
MedSastinal, hyperplasia, plasma cell
Mediastinal, inflammation, suppurative
Renal, hemorrhage
Lymph node, mandabular
Hypcrplasia, lymphoid
1-Iyperplasia, lymphoid, plasma cell
Hyperplssia, plasma cell
Lymph node, mesenteric
Congestion
cyst
Hematopoietic cell proliferation
Hyperplasia
F-IIyqserplasia, lymphoid
iiyperplasia, lymphoid, plasma cell
Thrombus
Spleen
Amploid deposition
Fibrosis
Eiematopoietic cell proliferation
Hypserplasim, lymphoid
Pigmentation, hemosidericr
Thymus
Ectopic parathyroid gland
High Dose
(5S)
(16)
(b5)
(22)
L (b9''o)
(54)
1 (29'0)
(54)
I (2%)
1 (S%)
1 (29b)
1 (2%)
1 (2%)
1 (2%)
Y 6210
1 (2%)
(50)
2 (4%)
d (2%).
(52)
1 (2g°o)
1 (2%)
I (2%)
1 (2%)
f (2%)
(55)
7 (13%)
1 (53"0)
B (99'a)
I
(16)
i (6%)
(53)
5 (9%)
1 (2%)
237
1 (2%)
(49)
1 (23'0)
1 (2%)
(52)
2 (4Wo)
(B?)
1 (6%)
2 (Y2~'o)
(22)
1 (5%)
2 (93`0)
1 (5'o)
1 (5%)
(44)
INTEGUMENTARY SYSTEM
Mammary gland
(52)
Hyperplasia
9 (l'ZR°o)
FIypeY[JI85L8, cystic
1 (°L°Io)
Inflammation, chronic
Duct, ectasia
1 (2%)
Skin
(55)
Ulcer
2 (4%)
Abdominal, subcutaneous tissue, abscess
Subcutaneous tissue, inflammation, suppurative
MUSCULOSKELETAL SYSTEM
Bone
Fibrous osteodystrophy
Joint, taesal,hyyserostosis
Low Dose
1 (29'0)
. 2 (4%)
(b5)
1 (2%)
4 (7~'0)
1 (2%)
(13)
(47)
(20)
1 (59'0)
(53)
5 (9%)
2 (4%)
1 (23'a)
(16)
1 (G%)
- 1 (6%)
(16)
(55)
4 (79b)
(b5)
3 (5%)
Hydroquinone, N'I'P'T"R 366
TABLE I)5. SUMMARY OF '1'&3E INCIDENCE (2F NONNEOPI.AS'I"IC LESIONS IN FEMALE MICE IN THE
TWO-YEAR GAVAGE STUDY OF FI'YI3ROQBTINODdE (Continued)
Vehicle Control
NERVOUS SYSTEM
Brain
Atrophy
Hemorrhage, focal
Mineralization
Cerebrum, hemorrhage
Cerebrum, inflammation, chronic, focal
RESPIRATORY SYSTEM
Lung
Atelectasis
Congestion
Hemorrhage, focal
Inflammation, chronic
Metaplasia, osseous
"
Alveolar epithelium, hyperplasia
Alveolus, hyperplasia, macrophage
Artery, hypertrophy
Artery, capillary, vein, Ienkocytosis
Peribronchiolar, inflammation, chronic
Perivascular, inflammation, chronic
Nose
Inflammation, acute
Nfacosa, inflammation, chronic
Nasolacrimal duct, foreign body
Nasolacrimal duct, inflammation, chronic
SPECIAL SENSES SYSTEM
Eye
Conjunctiva, retrobalbar, inflammation
Lacrimal gland
(55)
Low Dose
(1&)
5 (9%9)
1 (29'0)
(55)
1 (6%)
(55)
1 (23'0)
1 (2%)
1 (2%)
1 (23°0)
1 (2°l0)
1 (2%)
2 (4~'o)
(64)
1 (2%)
I (29°0)
(16)
i (69"0)
(2)
Renal tubule, pigmentation, hemossderin
Urinary bladder
Cytogrtegaly
MuscuIaris,submucosa,inflammation
Submucosa, inflammation, chronic
Submucasa, inflammation, heenorrhagic, chronic
Subserosa, inflammation, chronic
Hydroquinane ; NTI' TR 366
..
(55)
1 (2ePo)
$ (5%)
5 (9%)
1 (2%)
2 (4%)
1 f2%3
1 (2%)
1 (2%)
2 (4%)
(55)
1 (2°!0)
2 (4%)
1 (503'0)
1 (503b)
(55)
2 (4%)
1 (29b)
35 (6A9'o)
(16)
8 i50`9o9
1 (2%)
1 (25"0)
1 (2°l0)
(53)
1 (2%a)
28 (b3%)
(15)
4 (27%)
2 (7%)
238
-
(55)
1 (29'0)
1 (2%)
3 (6%)
(5)
1 (20%)
(2)
Inflammation, chronic
Eatraorbital, inflammation, chronic
URINARY SYSTEM
Kidney
Amqloid deposition
Glomerulosclerosis
Inflammation, chronic
11Ketsplasia,osseous,focal
Nephropathy
Cortex, fibrosis, focal
Cortex, metaplasia, osseous
Cortex, necrosis, focal
High Dose
(5b)
2 (4%a)
34
1
1
1
(62%)
(29'0)
(2%)
(2%)
(54)
1 (2R'o)
33
(61%)
1 (23'0)
°
I
APPENDIX E
SENTINEL ANIMAL PROGRAM
.
;
TABLF El
PAGE
MURINE VIRUS ANTIBODY DETERMINATIONS FOR RATS AND MICE IN THE
TWO-YEAR fiAVAGE STUDIES OF HYDROQUINONE
239
241
Hydroquinone, NTP TR 366
APP ENDIX E. SENTI NEL ANIMAL P
Methods
Rodents used in the Carciraogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results . The Sentinel
Animal Program is part of the periodic monitoring of animal health that occurs during the toxicolagif
evaluation of chemical compounds . Under this program, the disease state of the rodents is monitored
via viral serology on sera from extra (sentinel) animals in the study rooms . These animals are untreated, and these animals and the study animals are both subject to identical environmental conditions . The sentinel animals came from the same production source and cueanling groups as the animals used for the studies of chemical compounds .
Results
Results are presented in Table E1 .
Hydroquinone, N"I'P TR 366
240
i
,
;
;
TABLE E1 . NdtTRIleTE VIRUS ANTIBODY DETERMINATIONS FOR RATS AND MICE IN '!'HE TWO-YEAR
GAVAGE STUDIES OF HYDROQUINONE (a)
Number of
Animals
Positive Serologic
Reaction for
12
18
24
(b)
-9/10
9110
None positive
None positive
None positive
RC`71SDA °
RCV/SDA
6
12
18
24
-----
None positive
None positive
None positive
Norse positive
Interval (months)
RATS
5
MICE
(a) Blood samples were taken from two sick rats at 5 months and from sentinel animals at 6, 12, and 18 months after the start of
dosing and from the vehicle control animals just before they were killed; samples were sent to Microbiological Associates
(Bethesda, MD) for determination of antibody titers .
(b) No positive viral antibody titers were observed for the two sick rats tested.
241
Hydroqniraone, NTP TIt 366
APPE NDIX F
Pellet Diet: September 1 982 to October. 1984
(Manufactured hy Zeigler Bros., Inc ., Gardnerse PA)
PAGE
TABLE F1
INGREDIENTS OF NIH 07 RAT AND MOUSE RATION
244
TABLE F2
VITAMINS AND MINERALS IN 1VTH 07 RAT AND MOUSE RATION
244
TABLE F3
NUTRIENT COMPOSITION OF NIH 07 RAT AND MOUSE RATION
245
TABLE F4
CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION
246
243
Hydraquinone, NTP T1R. 366
TABLE Fl. INGREDIENTS OF NIH 07 RAT AND MOUSE RATION (a)
Ingredients (b)
Percent by Weight
Ground #2 yellow shelled corn
Ground hard winter wheat
Soybean meal (49% protein)
Fish meal (60% protein)
Wheat middlings
Dried skim milk
Alfalfa meal (dehydrated, 17% protein)
Corn gluten meal (60% protein)'
Say oil .
Dried brewer's yeast
Dry molasses
Dicalciurn phosphate
Ground limestone
Salt
Premixes (vitamin and mineral)
24.50
23 .00
12 .00
10 .00
10 .00
5_pp
4.00
3 .00
2 .50
8 .00
1 .50
1 .25
0 .50
0 .50
0 .25
(a) NCI, 1976; NIH,1978
(b) Ingredients ground to pass through a U.S. Standard Screen No . 16 before being mixed
TABLE F'2 . VITAMINS AND 1ViINEItALS IN vIH 07 RAT AND MOUSE RATION (a)
Amount
Source
Vitamins
t4
.
Dg
K3
d-a-Tocopheryl acetate
Choline
Folic acid
Niacin
d-Pantothenic acid
Riboflavin
Thiamine
B12
Pyridoxine
Biotin
5,500,000 ILT
Stabilized vitamin A palmitate or acetate
4,600,000 IU
2 .8 g
20,000 IU
560 .0 g
2 .2 g
30 .0 g
18 .0 g
3 .4 g
50 .0 g
I3-activated animal sterol
I04enadione
Choline chloride
d-Calcium pantothenate
Thiamine monanitrate
4,000 lig
1 .7 g
140 .0 mg
Pyridoxine hydrochloride
d-Biotin
Minerals
Iron
Manganese
Zinc
Copper
Iodine
Cobalt
120 .0 g
Iron sulfate
60 .0 g
Manganous oxide
16 .0 g
4 .0 g
1 .4 g
0 .4 g
Zinc oxide
Copper sulfate
Calcium P0C72CE'
Cobalt carbonate
(a) Per tan (2,000 lb) of finished product
Hydroquinone, NTP TR 366
244
TABLE F3 . NUTRIENT COMPOSITION OF NIH 07 RAT AND MOUSE RATION
Nutrients
Crude protein (percent by weight)
Crude fat (percent by weight)
Crude fiber (percent by weight)
Ash (percent by weight)
Mean ± Standard
Deviation
23 .05
522
3,49
6 .64
± 1 .06
± 0 .66
± 0 .52
± 0 .34
1 .32
0 .319
1 .146
0 .571
0 .914
1 .946
1 .280
0 .436
0 .938
0 .855
0 .277
0 .818
1 .108
±
±
±
±
±
±
±
±
±
±
±
±
±
Range
Number
of Samples
21 .3-26 .3
3 .3-8 .5
2.8-5 .6
6.1-71
26
26
26
26
Amino Acids (percent of total diet)
Arginine
Cystine
G4ycine
Histidine
Isoleueine
Leucine
Lysine
YYtethionine
Phenytalanine
Threonine
Tryptaphan
Tyrosine
Vsline
0 .072
0 .088
0 .063
0 .026
0 .030
0 .056
0 .067
0 .165
0 .158
0 .035
0 .2210 .086
0 .043
1 .310-1 .380
0.218-0 .400
3 .060-1 .210
0.531-0 .603
0.881-0 .944
1 .850-1 .930
1 .200-1 .370
0.306-0 .699
0 .665-1 .Q5
0.824-0 .898
0.156-0 .671
0.564-0 .769
1 .050-1 .170
5
5
5
5
5
5
5
5
5
5
5
5
5
2 .290 ± 0 .313
0 .258 ± 0 .040
1 .83-2 .52
0210-0 .308
5
5
± 4,593
± 1,382
~- 6.82
± 3 .95
± 0.85
~- 31 .68
± 4_31
± 1 .31
± 0_89
± 0.053
± 12 .66
± 416 .8
4,100-24,000
3,000-6,300
31 .2.-48 .0
12 .Q-27 .0
6.10-8 .2
65 .0-150 .0
23 .0-34 .0
5 .60-8 .8
1 .&0-3 .7
0 .19-0 .32
10 .6-38 .0
2,400-3,430
26
4
5
26
5
5
5
5
5
5
5
5
±
~±
±
±
t
±
±
±
-E'
±
±
-!±
0 .35-1 .fi3
0 .87-1 .10
0 .772-0 .971
0 .380-0 .635
0 .255-0.371
O .fl51-0.181
0 .268-0.420
268 .0-523 .0
81 .7-99 .4
46.1-582
5 .09-15 .39
1 .52-3.82
1 .44-2.09
0 .490-0.780
26
26
3
5
5
6
5
5
5
5
b
4
5
4
Essential Fatty Acids (percent of tot al diet)
Linoleic
Linolenic
Vitamins
Vitamin A (IU/kg)
Vitamin D (IU1kg)
a-Tocopherol (ppm)
Thiamine (ppm)
Riboflavin (ppm) .
Niacin (ppm)
Pantothenic acid (ppm)
Pyridoxine (ppm)
Folic acid (ppm)
Biotin (ppm)
Vitamin B12 (ppb)
Choline(ppm)
12,353
4,450
43 .58
1&23
7 .6
97 .8
30 .06
7 .68
2 .62
0 .254
2421
3,fl22
Minerals
Calcium (percent)
Phosphorus (percent)
Potassium (percent)
Chloride (percent)
Sodium (percent)
Magnesium (percent)
Sulfur (percent)
Iron (ppm)
Manganese (ppm)
Zinc (ppm)
Copper (ppm)
Iodine (pgm)
Chromium (ppm)
Cobalt (ppm)
1 .29
0 .96
0 .900
0 .513
0 .323
0 .167
0 .304
410 .3
9G29
52 .78
10 .72
2 .95
1,85
0 .681
0.16
0.0&
0 .09$
0 .114
0 .043
0.012
0 .064
94.04
7 .15
4 .94
2 .76
1 .05
025
0 .14
245
Hydroquinone, NTP'FR 366
TABLE F4. CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION
Contaminants
,
Arsenic (ppm)
Cadmium (ppm) (a)
Lead (ppm)
Mercury (ppm) (a)
Selenium (ppm)
Aflatogins (ppb) (a)
Nitrate nitrogen (ppm) (b)
Nitrite nitrogen (ppm) (b)
BHA (ppm) (c)
$HT (ppm) (c)
'
Aerobic plate count (CFU/g) (d)
Coflifosin (MPIeI/g) (e)
E . coti (MFPd/g) (e)
Total nitrosamines (ppb) (f)
N-Niteosodimethylamine (ppb) (f)
1V-IiTitrosopyrrolidine (ppb) (f)
Mean ± Standard
Deviation
0 .53 ± 0 .16
<0 .10
0 .62 ± 0 .29
<O .05
0 .32 ± 0 .07
<u .0
937 ± 4 .63
1 .09 ± 1 .60
3 .77 ± 4 .67
236 ~- 2 .49
44,858 ± 34,551
56 .73 ~- 128
3,f)4 ± 0.20
5 .60 ± 5 .63
4 .55 ± 5 .65
1 .134 ± 0.24
Range
0 .17-0.77
0 .33-1 .63
0.13-0.42
0.10-22 .0
0.10-?24
2.00-17 .fl0
1 .00-12 .00
7,1OQ=130,000
3 .0-460
3 .Od-4 .00
4 .8-30 .90
0 .8-30 .00
0 .$P-1 .70
Number
of Samples
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
Pesticides (ppm)
a-BI-IC (a,g)
P-BF¬ C (a)
y-BiiC (a)
S-BHC (a)
Heptachlor (a)
Aldsin (a)
Heptachlor epoxide (a)
d)DE (a)
I9Dd) (a)
DDT (a)
IICB (a)
1Vlireg (a)
112ethogychlor (a)
I3ieldrin (a)
Endrin (a)
3'elodrin (a) Chlordane (a)
Toxaphene (a)
Estimated PCBs (a)
iionnei (a)
Ethion (a)
Tritlxion (a)
I3iaainon (a)
Methyl parathion (a)
Ethyl parathion (a)
iaialathion(h)
Endosuif'an d (a)
Endosulfan II (a)
Endosalfan sulfate (a)
<0 .01
< 0 .02
<0 .01
<0 .01
<p .pg
<0 .01
<0 .01
<0 .01
<0 .01 '
<0 .01
<0 .01
<0 .01
<0 .05
<0 .01
<0 .01
<0 .01
<0 .05
<0.1
<0.2
<0.01
<0.02
<O .Ob
<0 .1
<0 .02
<0,02
(7.12 ± 0 .09
cp,pg
<0 .01
<0 .03
0.05-0 .43
(a) All values were less than the detection limit, given in the table as the mean
.
(b) Source of contamination : alfalfa, grains, and fish meal
(c) Source of contamination: soy oil and fish meal
(d) CFU = colony-forming unit
(e) MP1V = most probable number
M All values were corrected for percent recovery .
(g) BHC = hegachlorocyclohexane or benzene hexachloride
(h) Fifteen lots contained more than 0.05 ppm .
H3rdroquinone, NTP TFt 366
246
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
AUDIT SUMMARY
247
Hydroquinone,lVTP TR 366
APPENDIX G. AUDIT SUMMARY
The pathology specimens, experimental data, study documents, and draft of NTP Technical Report
No. 3&6 for the 2-year studies of hydroquinone in rats and mice were audited for the National Institute of Environmental Health Sciences (NIEHS) at the National. Toxicology Program (N'TP) Archives
by resource support contractors . The audit included review of
(1)
(2)
Alt records concerning animal receipt, quarantine, randomization, and disposition prior to
study start.
All inlif'e records including protocol, correspondence, animal husbandry, environmental conditions, dosing, external masses, mortality, animal identification., and serology .
(3) Body weight and clinical observation data; all data were scanned before individual data for a
random 10% or 20% sample of animals in each study group were reviewed in detail .
(4) All chemistry records .
(5) . All postmortem records for individual animals concerning date of death, disposition codes,
condition codes, tissue accountability, correlation of masses or clinical signs recorded at the
last inlife observation with gross observations and microscopic diagnoses, and correlations between gross observations and microscopic diagnoses.
(6)
(7)
(8)
(9)
A11 wet tissue bags far inventory and wet tissues from a random 20°lo sample of animals in vehicle control and high dose groups, plus other relevant cases to verify animal identity and to
examine for untrimmed potential lesions.
Blocks and slides of tissues from a random 20% sample of animals from vehicle control and
high dose groups and animals with less than complete or correct identification .
Necropsy records forms for data entry errors and all microscopic diagnosis updates for a random 10% sample of animals to verify incorporation into final pathology tables .
Correlation between the data, factual information, and procedures for the 2-year studies presented in the draft of the Technical Report and the records available at the IVTP Archives .
Procedures and events during the exposure phase of the studies were documented adequately by the
archival records with the exception of some or all of the records for balance calibration, room light
cycle, cage changes, and cage environment observations and mean differential leukocyte values for
female mace . Records documented that doses were prepared, analyzed, arid administered to animals
properly . Review of 84 group mean body weight values showed 3 errors of small magnitude (0 .1°l0 ±
0.7%) . Observations of clinical signs and masses were made consistently . Of the external masses
noted in the inlife records, 128/148 in rats and 78193 in mice correlated with necropsy observations ;
those that did not correlate were distributed evenly across the study groups . Survival records for all
unscheduled-death animals were reviewed and found to be correct, except for the reason for removal
of one rat and two mice ; correct information for these is presented in the N`I'P Technical Report .
Individual animal identifiers (punched ears) were present in the residual wet tissues and correct for
72l121 rats and 73/76 mice examined . Improper marking of ears or their mutilation appeared to be
responsible for less than complete or correct identifiers in the remaining animals; gender was correct
in every case and review of data trails for these animals provided evidence that the integrity of their
individual animal identity had been preserved throughout the studies. The residual wet tissues contained five untrimmed potential lesions in rats and one in a mouse . Microscopic diagnoses for intestines were made and correlated with gross lesions, but some intestinal segments in the residual wet
tissues were incompletely opened . Tissue blocks and slides matched and were labeled correctly. All
gross observations made at necropsy correlated with microscopic diagnoses.
Full details about these and other audit findings are presented in the audit reports on file at the
NIEHS. In conclusion, the data ane~ factual information presented in the preliminary draft of the
Technical Report for the 2-year gavage studies of hydroquinane are supported by the records at the
N'I'P Archives .
I-Iydroqubnone, N'I'P TR 366
248
NATIONAL TOXICOLOGY PROGRAM TECHNICAL REPORTS
P RINTED As OF SEPTEMBER 1989
TR No.
,
!
i
i
I
'
CHEMICAL
TR No .
201
206
207
208
209
210
211
212
213
214
215
216
217
219
220
221
222
223
224
225
226
227
229
230
231
233
234
235
236
238
239
240
242
244
2,3,7,8-Tetrachlorodibenzo-p-dioxin (Dermal)
Dibromochloropropane
Cytembena
FD 8c C Yellow No . 6
2,3,7,8-Tetrachlorodibenzo-p-dioxin (Gavage)
1,2-Dibromoethane (Inhalation)
C .Y . Acid Orange 10
Di(2-ethylhegyi)adipate
ButylbenzylPhthalate
Capro4actam
Bisphenol A
lY-AminaundecanoicAcid
Di(2-ethylhegyl)phthalate
2,6-Dichloro-p-phenylenediamine
C .I. Acid Red 14
Locust Sean Gum
C .I . Disperse Yellow 3
EugenoP
'I'ara Gum
D & C Red No. 9
C .I . Solvent Yellow 24
Gum Arabic
Guar Gum
Agar
Stannous Chloride
2-Biphenylarnine Hydrochloride
Allyl Isothiocyanate
Zearalenone
n-Mannitot
Ziram
Bis(2-chloro-l-methylethyl)ether
Propyi Galiate
I)iallyl Phthalate (Mice)
1'olybrominated Biphenyl Mixture
287
288
289
291
293
294
295
286
24`d
248
249
250
251
252
263
255
257
259
261
263
266
2&7
269
271
272
273
274
275
2?6
280
281
282
2$4
285
r.-Ascorbic Acid
4,4°-MethylenedianilineDihydroch9oride
Amosite Asbestos
BenzylAcetate
Toluene Diisocyanate
Gerany1 Acetate
Allylisovalerate
1,2-Dichiorobenzene
Digi;ycidyl Resorcinol Ether
Ethyl Acrylate
Chlorobenzene
1,2-Dichloropropane
Nionuron
Propylene Oxide
Telone HO
HC Blue No . 1
Propylene
Trichloroethylene (Four strains of rats)
Tris(2-ethythexyl)phosphate
2-Chloroethanol
8-Kydroxyquinoline
Crocidolite Asbestos
HC Red No . 3
Chlorodibromomethane
I3ia11yiphthalate (Rats)
C .I . Basic Red 9 Monohydrochloride
326
327
328
329
330
331
332
333
334
335
336
337
338
339
343
344
345
348
349
350
363
356
357
358
369
361
245
Melamine
298
299
300
301
303
304
305
306
307
308
309
310
311
312
314
315
316
317
318
319
320
321
322
323
324
325
CHEMICAL
Dimethyl Hydrogen Phosphite
1,3-Butadiene
Benzene
Isophorone
HC Blue No . 2
Chlorinated Trisodium Phosphate
Chrysotile Asbestos (Rats)
Tetrakis(hydroxymetAyl)phasphonium Sulfate and
Tetrakis(hydroxymethyl)phosphonium Chloride
Ditnethyi Morpholinaphosphoramidate
C .T. Disperse Blue 1
3-Chloro-2-methylpeopsne
o-Phenylphenol
4-Vinylcyclohesene
Chlorendic Acid
Chlorinated Paraffins (C23, 43% chlorine)
LDichloromethane
Ephedrine Sulfate
Chlorinated Faraffins (C12,60% chlorine)
ISecabromadighenyl Oxide
Marine Diesel Fuel and JP-5 Navy Fuel
TeCrachiaroethylene (Inhalation)
n-Butyl Chloride
Methyl Methaerylate
Oxytetracycline Hydrochloride
1-Chloro-2-methylpropene
Chlorphenieamine 1VIaIeate
Ampicillin Trihydrate
1,4-Dichlorobenaene
Rotenone
Sromodichforomethane
Phenylephrine Hydrochloride
Dimethyl M[ethylphosphonate
Boric Acid
Pentachloronitrobenzene
Ethylene Oxide
Xylenes(Mixed)
Methyl Carbamate
1,2-Epaxybutane
4-Hexylresorcinol
Matonaldehyde, Sodium Salt
Mercaptobenzothiazole
N-Phenyl-2-naphthylamine
2-Amino-5-nitrophenol
C .I . Acid Orange 3
Penicillin VK
Nitrofurazone
Erythromycin Stearate
2-Amino-4-nitrophenal
Benzyl Alcohol
Tetracycline Hydrochloride
Roxarsone
a-i4fethyldopa Sesquinydrate
Pentachlorophenol
Tribromomethane
2,4-Dichlorophenoi
Furosemide
Hydrochflorothiazide
Ochratosin A
8-Methoxypsoralen
Hexachloroethane
These IlTTP Technical Reports are available for sale from the National Technical Information Service, U .S . Department of
Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-4&7-4650) . Single copies of this Technical Report ace available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P .O .
Box 12233, Research Triangle Park, NC 2770ct .